Laboratory technique to multiply a DNA sample for study
POPULARITY
Categories
55 episodes with pcr
63 episodes with pcr
26 episodes with pcr
24 episodes with pcr
24 episodes with pcr
18 episodes with pcr
18 episodes with pcr
31 episodes with pcr
16 episodes with pcr
37 episodes with pcr
12 episodes with pcr
49 episodes with pcr
18 episodes with pcr
10 episodes with pcr
9 episodes with pcr
27 episodes with pcr
14 episodes with pcr
8 episodes with pcr
19 episodes with pcr
16 episodes with pcr
9 episodes with pcr
8 episodes with pcr
10 episodes with pcr
8 episodes with pcr
12 episodes with pcr
21 episodes with pcr
12 episodes with pcr
16 episodes with pcr
21 episodes with pcr
15 episodes with pcr
10 episodes with pcr
20 episodes with pcr
20 episodes with pcr
20 episodes with pcr
13 episodes with pcr
14 episodes with pcr
12 episodes with pcr
13 episodes with pcr
10 episodes with pcr
5 episodes with pcr
18 episodes with pcr
8 episodes with pcr
10 episodes with pcr
8 episodes with pcr
6 episodes with pcr
8 episodes with pcr
10 episodes with pcr
10 episodes with pcr
8 episodes with pcr
9 episodes with pcr
4 episodes with pcr
5 episodes with pcr
13 episodes with pcr
20 episodes with pcr
7 episodes with pcr
4 episodes with pcr
8 episodes with pcr
7 episodes with pcr
4 episodes with pcr
8 episodes with pcr
7 episodes with pcr
9 episodes with pcr
10 episodes with pcr
8 episodes with pcr
13 episodes with pcr
6 episodes with pcr
7 episodes with pcr
18 episodes with pcr
5 episodes with pcr
10 episodes with pcr
8 episodes with pcr
13 episodes with pcr
8 episodes with pcr
7 episodes with pcr
12 episodes with pcr
12 episodes with pcr
7 episodes with pcr
4 episodes with pcr
7 episodes with pcr
3 episodes with pcr
12 episodes with pcr
5 episodes with pcr
7 episodes with pcr
7 episodes with pcr
5 episodes with pcr
4 episodes with pcr
11 episodes with pcr
5 episodes with pcr
6 episodes with pcr
3 episodes with pcr
5 episodes with pcr
5 episodes with pcr
7 episodes with pcr
10 episodes with pcr
9 episodes with pcr
5 episodes with pcr
6 episodes with pcr
3 episodes with pcr
6 episodes with pcr
6 episodes with pcr
4 episodes with pcr
6 episodes with pcr
3 episodes with pcr
4 episodes with pcr
5 episodes with pcr
7 episodes with pcr
4 episodes with pcr
6 episodes with pcr
7 episodes with pcr
6 episodes with pcr
6 episodes with pcr
6 episodes with pcr
5 episodes with pcr
4 episodes with pcr
3 episodes with pcr
13 episodes with pcr
5 episodes with pcr
5 episodes with pcr
3 episodes with pcr
9 episodes with pcr
4 episodes with pcr
5 episodes with pcr
3 episodes with pcr
4 episodes with pcr
3 episodes with pcr
7 episodes with pcr
2 episodes with pcr
8 episodes with pcr
6 episodes with pcr
12 episodes with pcr
3 episodes with pcr
5 episodes with pcr
5 episodes with pcr
2 episodes with pcr
13 episodes with pcr
4 episodes with pcr
3 episodes with pcr
4 episodes with pcr
8 episodes with pcr
4 episodes with pcr
5 episodes with pcr
5 episodes with pcr
4 episodes with pcr
2 episodes with pcr
4 episodes with pcr
2 episodes with pcr
3 episodes with pcr
5 episodes with pcr
6 episodes with pcr
4 episodes with pcr
5 episodes with pcr
4 episodes with pcr
4 episodes with pcr
3 episodes with pcr
7 episodes with pcr
7 episodes with pcr
4 episodes with pcr
4 episodes with pcr
3 episodes with pcr
2 episodes with pcr
4 episodes with pcr
9 episodes with pcr
Pop Culture Revolution has moved to a new home! Absolute DMV Podcast Network! DJ Boss Player and Mori christened the new season! DJ Boss Player's wife brought cake and champagne to celebrate! They caught up on all the hot topics they missed since the last episode in May! And they took a "Deep Dive" into the topic of capitalism in the USA! And now we're going to have video content in addition to the audio distribution! Look out for it in the coming days! We're back with a new swag and better than EVER! Join the Revolution!
If you've been trying to conceive with low AMH, high FSH, diminished ovarian reserve (DOR), or poor egg quality and nothing seems to be working… or if you've experienced failed IVF cycles or unexplained pregnancy loss - this episode is for you. We're diving into one of the most overlooked infections that could be silently impacting your fertility: Ureaplasma. This commonly missed microbe can compromise egg quality, disrupt implantation, and contribute to early miscarriage, even when labs appear “normal.” Whether you're TTC naturally or preparing for an IVF or FET cycle, you'll learn: How Ureaplasma affects egg and embryo quality, implantation, and ovarian reserve Why this infection is often missed on standard fertility workups The importance of partner testing and treating both partners When and how to test for Ureaplasma The functional fertility approach we use at Fab Fertile to rebalance the vaginal and seminal microbiome for optimal conception If you've done “all the things” and still aren't seeing results, this episode may reveal a missing piece of your fertility puzzle. This episode is for you if: You're struggling to conceive naturally despite doing “all the right things.” You've had failed IVF transfers, poor egg quality, or low ovarian reserve without clear answers. You've experienced recurrent infections or unexplained pregnancy losses. 5 Key Points: Why Ureaplasma and Mycoplasma are often missed in standard fertility testing and why they matter for egg quality, implantation and pregnancy maintenance. How Ureaplasma can contribute to low AMH, high FSH, and diminished ovarian reserve by increasing inflammation in the reproductive tract and altering the vaginal microbiome. The link between Ureaplasma and recurrent miscarriage, failed IVF, and abnormal embryos, even when other tests are “normal”. The functional fertility approach to addressing Ureaplasma with targeted antimicrobials, vaginal microbiome restoration, and gut health support for natural and assisted conception. --- TIMESTAMPS [00:00:00] Intro: Ureaplasma's hidden role in fertility struggles, natural conception, failed IVF, low AMH, DOR, poor egg quality, and unexplained pregnancy loss. [00:01:00] Who this episode is for: Fertility challenges including low AMH, high FSH, DOR, RPL, recurrent infections, and unexplained infertility. [00:02:00] What is ureaplasma? Impact on vaginal and seminal microbiome, egg and sperm quality, inflammation, and implantation failure. [00:03:00] Who should get tested? Those with unexplained infertility, recurrent pregnancy loss, persistent infections, elevated CRP/ANA, poor IVF outcomes, or partner infection history. [00:04:00] Why microbiome testing matters: Gut, vaginal, and seminal microbiome panels uncover hidden infections missed by conventional testing. [00:05:00] Key red flags: Multiple failed IVF transfers, RPL after heartbeat confirmation, chronic vaginal/urinary symptoms, and abnormal semen analysis. [00:06:00] Testing methods: Functional medicine/nutrition, PCR, and microbiome panels (e.g., Juno Bio) versus limited conventional testing. [00:07:00] Supporting Fertility Success: Using biofilm disruptors and restoring balance in gut and vaginal microbiomes to improve egg quality and IVF outcomes. --- How to Get Started With Functional Fertility Support Book your call here to get your personalized plan and options to help improve pregnancy success either naturally or with IVF treatment. Check out our Fab Fertile functional fertility program here and learn how to improve AMH levels naturally. We work with couples that have low AMH, high FSH, diminished ovarian reserve, premature ovarian insufficiency, and recurrent pregnancy loss. --- RESOURCES Before Your IVF Transfer, Test This First: https://fabfertile.com/blogs/podcasts/before-your-ivf-transfer-test-this-first?_pos=4&_sid=c1bed4027&_ss=r IVF Prep with Low AMH: Boosting Your Chances for Success: https://fabfertile.com/blogs/podcasts/ivf-prep-with-low-amh-boosting-your-chances-for-success-1?_pos=1&_sid=2685fd59c&_ss=r Causes of Miscarriage Before 12 Weeks: What Most Doctors Miss: https://fabfertile.com/blogs/podcasts/causes-of-miscarriage-before-12-weeks-what-most-doctors-miss What You Need To Know About Chronic Infections And Infertility: https://fabfertile.com/blogs/podcasts/what-you-need-to-know-about-chronic-infections-and-infertility?_pos=2&_sid=1142152ce&_ss=r Our favorite fertility tracker Inito (use code FABFERTILE15 to save 15) Studies Today's study looks at Ureaplasma urealyticum, a common genital tract infection, and how it affects IVF. Researchers found it didn't affect fertilization or embryo quality but was linked to lower pregnancy rates after embryo transfer. The culprit? Infection in the endometrial lining which can disrupt implantation. So even if embryos look good Ureaplasma can still sabotage IVF success. https://academic.oup.com/humrep/article-abstract/6/5/727/609246?redirectedFrom=fulltext This study looked at whether Ureaplasma urealyticum in men's semen affects IVF. The results? Fertilization and pregnancy rates were the same for infected and uninfected men. But here's the thing, miscarriage rates were much higher in couples where the male partner had the infection. So Ureaplasma might not stop you from getting pregnant but it can increase the risk of losing the pregnancy. https://www.fertstert.org/article/S0015-0282(98)00472-5/fulltext Ultimate Guide to Getting Pregnant This Year If You Have Low AMH/High FSH ---
FREEDOM - HEALTH - HAPPINESSThis podcast is highly addictive and seriously good for your health.SUPPORT DOC MALIK To make sure you don't miss any episodes, have access to bonus content, back catalogue, and monthly Live Streams, please subscribe to either:The paid Spotify subscription here: https://creators.spotify.com/pod/show/docmalik/subscribe The paid Substack subscription here: https://docmalik.substack.com/subscribeThank you to all the new subscribers for your lovely messages and reviews! And a big thanks to my existing subscribers for sticking with me and supporting the show! ABOUT THIS CONVERSATION: Attorney Tom Renz and I dig into the lies, fear tactics, and deep state manipulation that defined the COVID plandemic. From rigged PCR testing to the PREP Act's corporate immunity, we expose the fraud, call out weak leadership, and talk about the personal cost of fighting for truth and freedom. This is about courage, accountability, and the battle for our children's future.See my substack for more information.Much love, as always.Doc MalikLinksWebsite https://tomrenz.com/IMPORTANT INFORMATIONCONSULTATION SERVICEIn a world of rushed 7-minute consultations and endless referrals, I offer you something rare: time, context, and clear guidance.As your health advocate, I can help you:Understand your diagnosis and decode medical jargonDecide who to see: GP, specialist, osteopath, physio, accupuntcurist, homeopath etc?Break down treatment plans in plain, easy to understand non jargon EnglishPrepare for surgery, understand your risks, obtain true informed consent, and optimise yourself pre-op Recover from surgery, advise you how to heal faster and quicker and minimise post-op complicationsManage chronic illness with lifestyle, mindset, and dietary changesExplore holistic options that complement conventional careImplement lifestyle changes like fasting, stress reduction, or movementAsk better questions, and get real answersGet an unbiased second opinionReady to Take Control?If you're navigating a health concern, preparing for a big decision, or simply want to feel more confident in your path forward, I'd love to support you.Book here https://docmalik.com/consultations/ Because it's your body, your life, and your future. Let's make sure you're informed and heard.WaterpureI distill all my water for drinking, washing fruit and vegetables, and cooking. If you knew what was in tap water, so would you!https://waterpure.co.uk/docmalik BUY HERE TODAYHunter & Gather FoodsSeed oils are inflammatory, toxic and nasty; eliminate them from your diet immediately. Check out the products from this great companyhttps://hunterandgatherfoods.com/?ref=DOCHG BUY HERE TODAYUse DOCHG to get 10% OFF your purchase with Hunter & Gather Foods.IMPORTANT NOTICEIf you value my podcasts, please support the show so that I can continue to speak up by choosing one or both of the following options - Buy me a coffee If you want to make a one-off donation.Doc Malik Merch Store Check out my amazing freedom merch
Nesse episódio, o Dr. Vinícius Zofoli, intensivista e editor-chefe de terapia intensiva do portal Afya, discute como utilizar a ecocardiografia no contexto da PCR. Aperte o play e ouça agora! Confira esse e outros posts no Portal Afya e siga nossas redes sociais!FacebookInstagramLinkedinTwitter
Ready to get real about breast augmentation? In this episode, we're diving deep into the world of cosmetic surgery with a no-holds-barred conversation you won't want to miss! Today, Dr. Robert Whitfield speaks with a patient, Kathy Dixon, who's here to share her personal journey. Kathy opens up about how her cultural background shaped her decisions, her struggles with breast implant illness, and what led her to choose explant surgery. Tune in to hear so much more! Kathy's Business, Oh Yes Communications (https://www.ohyescommunications.com/author/kathy/) Show Highlights: Kathy's Cultural Influences & Decision for Augmentation (00:02:45) *Kathy discusses her Colombian heritage, body image, and initial decision to pursue breast augmentation. *Cultural Trends in Plastic Surgery (00:08:21) South American vs. U.S. beauty standards, Brazilian butt lifts, and safety concerns. Fat Transfer Misconceptions & Technical Details (00:09:11) Differences between fat transfer to buttocks, face, and breasts, and addresses misconceptions Kathy's Surgical Journey & Onset of Symptoms (00:16:29) *Kathy recounts her initial surgery, complications, and the gradual onset of physical and emotional symptoms. *Medical Dismissal & Search for Answers (00:18:36) Being dismissed by doctors, pursuing hormone testing, and discovering breast implant illness Testing, Mold, and Mycotoxins (00:20:34) High mold count; surgeon discusses PCR testing, bacterial contamination, and importance of thorough pathology Challenges in Women's Health & Medical Gaslighting (00:28:00) Lack of support for women, medical gaslighting, and inappropriate reliance on birth control for hormone issues Mold, Detoxification, and Environmental Factors (00:33:37) *Environmental and dietary sources of mold, detox challenges, and lifestyle changes *Post-Surgery Recovery & Lifestyle Adjustments (00:44:11) *Recovery goals, physical therapy, emotional healing, and the importance of support systems *Support Systems & Patient Experience (00:48:25) Importance of family support, patient education, and realistic expectations for recovery Links and Resources Let's Connect Podcast: https://podcasts.apple.com/gb/podcast/breast-implant-illness/id1678143554 Spotify: https://open.spotify.com/show/1SPDripbluZKYsC0rwrBdb?si=23ea2cd9f6734667 TikTok: https://www.tiktok.com/@drrobertwhitfield?t=8oQyjO25X5i&r=1 IG: https://www.instagram.com/breastimplantillnessexpert/ FB: https://www.facebook.com/DrRobertWhitfield Linkedin: https://www.linkedin.com/in/dr-robert-whitfield-md-50775b10/ X: https://x.com/rob_whitfieldmd Read this article - https://www.breastcancer.org/treatment/surgery/breast-reconstruction/types/implant-reconstruction/illness/breast-implant-illness Shop: https://drrobssolutions.com SHARP: https://www.harp.health NVISN Labs - https://nvisnlabs.com/ Get access to Dr. Rob's Favorite Products below: Danger Coffee - Use our link for mold free coffee - https://dangercoffee.com/pages/mold-free-coffee?ref=ztvhyjg JASPR Air Purifier - Use code DRROB for the Jaspr Air Purifier - https://jaspr.co/ Echo Water - Get high quality water with our code DRROB10 - https://echowater.com/ BallancerPro - Use code DRROBVIP for the world's leader in lymphatic drainage technology - https://ballancerpro.com Ultrahuman - Use code WHITFIELD10 for the most accurate wearable - https://www.ultrahuman.com/ring/buy/us/?affiliateCode=drwhitfield
En este episodio de BreastLink, el Dr. Juan Carlos Samamé, oncólogo médico y vicepresidente de LABCA en Lima, Perú, da la bienvenida al Dr. Aleix Prat, oncólogo médico, cofundador de Reveal Genomics y director del Centro de Cáncer del Hospital Clínic de Barcelona, España. Juntos nos hablan sobre el papel de la prueba HER2 DX en la práctica clínica.Dentro de su conversación, se plantearon las siguientes preguntas:¿Qué es HER2 DX y en qué escenarios clínicos se recomienda utilizarlo para pacientes con cáncer de mama HER2 positivo?¿Qué procesos biológicos y variables clínicas analiza HER2 DX y cómo integra esta información para predecir pronóstico y respuesta patológica completa?¿Cómo puede ayudar HER2 DX en la toma de decisiones en tumores pequeños (estadio I) respecto a desescalar o intensificar la quimioterapia más trastuzumab?¿De qué manera HER2 DX contribuye a decidir entre cirugía primaria y neoadyuvancia en tumores borderline (1–2 cm, ganglios negativos)?¿Qué evidencia existe sobre el beneficio de añadir pertuzumab en pacientes clasificadas como PCR-high según HER2 DX, y cómo influye esto en la elección del esquema de tratamiento?Entre otras.Fecha de grabación: 24 de julio de 2025.Referencia:Este contenido se basa en la interpretación crítica de la evidencia científica disponible, así como en la experiencia clínica del o los ponentes como profesionales de la salud en instituciones de referencia.Para profundizar en los conceptos discutidos, se recomienda al profesional de la salud consultar literatura científica vigente, guías clínicas internacionales y la normatividad aplicable en su país.
Maryam Heinen is the author of Operation George Floyd. Get the book or documentary at www.maryamhenein.comLow Value Mail is a live call-in show with some of the most interesting guests the internet has to offer.Every Monday night at 7pm ETSupport The Show:
In this follow-up conversation with Raw Farm's CEO & Founder Mark McAfee, we explore the nuanced differences between raw milk and UV pasteurization technology. Mark shares his expert perspective on UV treatment as a middle ground between raw milk and traditional heat pasteurization, explaining why it preserves some bioactives while eliminating the beneficial bacterial diversity that makes raw milk unique.We dive into the technical aspects of milk safety, including Raw Farm's advanced PCR testing protocols that provide daily pathogen screening, and discuss the practical challenges of scaling raw milk production. Mark also shares his guide on how to source clean raw milk from your local farm. About Mark McAfeeMark McAfee founded the Raw Milk Institute (RAWMI) in 2011 to assure that farmers had a resource to assist them in producing very low risk raw milk for their consumers. Mark is passionate about “grass to glass” risk reduction management on the farm, and he believes that raw milk cannot emerge as a trusted food unless it is very low risk. He is certified in HACCP management from Chapman University and has developed and implemented award winning Food Safety Plans including Raw Milk Risk Analysis & Management Plans (“RAMP”).Links & ResourcesIntro to raw milk episode with Mark McAfee and Max KaneBob Comstock episode on UV pasteurization technologyGuide: How to Find a Good Raw Milk FarmerRaw milk finder: https://www.realmilk.com/raw-milk-finder/Raw Farm website: https://rawfarm.comCornell University 2021 study on bioactives in milkDiscounts Get 10% off delicious local farm-fresh food delivered to your door with my link for FarmMatch: https://farmmatch.com/jane Get 15% off high-quality Italian olive oil with code FARMTOFUTURE: https://shop.vignolifood.com/FARMTOFUTURE Get 40% the CircleDNA's Premium DNA test with code JANEZHANG: https://circledna.com/premium Connect with Jane Z. Instagram: @farm.to.future Email: jane@farmtofuture.co Website: farmtofuture.co
Hacer lo básico y hacerlo bien, es una buena forma de enfrentar pacientes en estado grave y en ambientes complejos. Las compresiones torácicas son la técnica de reanimación más básica que podemos hacer con un paciente en Paro Cardiorespiratorio (PCR) estas mantendrán un flujo de sangre a cerebro y corazón aumentado las posibilidades de sobrevivir de la víctima. Tienen algunos criterios que debemos cumplir para que puedan ser de calidad, Frecuencia y Profundidad son los más conocidos. Los dispositivos de retroalimentación son elementos que nos ayudan a objetivar los valores de estas variables y permitirnos entregar una RCP de alta calidad. Su uso esta recomendado hace bastante tiempo en escenarios de simulación y adquisición de habilidades de RCP ¡Pero son tan útiles en la atención del paciente en PCR?Marcan una diferencia real?Son preguntas muy válidas a las que te invito podamos juntos buscar una respuesta. En este episodio hablamos de un estudio que puede cambiar tu forma de ver estos dispositivos de retroalimentación. Espero que lo disfrutes! David Larrondo Fonseca. Links de Interés: IG: @emergencia24.7podcastZoll: www.zoll.comDiplomado Urgencia Emergencia y Desastres, PUC:https://educacioncontinua.uc.cl/programas/diplomado-en-atencion-en-urgencias-emergencias-y-desastres/The Role of Different Feedback Devices in the Survival of Patients in Cardiac Arrest: Systematic Review with Meta-Analysishttps://pmc.ncbi.nlm.nih.gov/articles/PMC11477487/
In this episode of The ICHE Podcast, we take a deep dive into the evolving role of plasma cell-free DNA (cfDNA) metagenomic next-generation sequencing (mNGS) in the diagnosis of infectious diseases. Hosted by experts from UCLA Health, this discussion breaks down what cfDNA mNGS is, how it differs from more traditional pathogen detection tools like PCR, and where it fits in the diagnostic landscape. Dr. Ishminder Kaur, Dr. Daniel Uslan, and Dr. Shangxin Yang join the episode to explore the clinical utility, benefits, and pitfalls of this rapidly emerging diagnostic modality. The group reviews several individual studies, highlighting how they approached their research questions, key findings, and the implications for patient care and antimicrobial stewardship. The conversation also addresses challenges such as interpreting complex results, cost considerations, and potential overuse. Whether you're a clinician, laboratorian, or infection preventionist, this episode provides critical insights into when and how cfDNA mNGS may enhance your diagnostic toolkit—and when it might not. Each guest closes with a practical takeaway: concrete advice for healthcare professionals who are considering incorporating cfDNA testing into their own clinical or infection control practice.
Can you detect Alzheimer's with a spit sample? That's the question driving Arianna Arbona's exciting research at Universidad Pablo de Olavide in Sevilla, Spain. In this episode of Absolute Gene-ius, she shares how she's isolating microvesicles from saliva and blood to identify early biomarkers for neurodegenerative diseases like Alzheimer's—an effort that could one day lead to minimally invasive diagnostic tools.Arianna describes the scientific and technical hurdles she's overcoming, from low vesicle concentrations to validating the brain-specific origin of those vesicles. She also reflects on her previous lupus research, where digital PCR enabled detection of faint mRNA signatures that qPCR missed—making it an essential tool for rare target quantification. Her future plans include integrating immuno-PCR and multiplex assays for more sensitive and multi-marker detection in Alzheimer's and beyond.In the career corner, Arianna recounts her journey from the Canary Islands to Helsinki to Sevilla, balancing passion, mentorship, and a healthy sense of humor. She talks about working through uncertainty after her master's degree, the mentors who kept her smiling, and how an early accidents taught her resilience. Her message to aspiring scientists: follow your curiosity and don't be afraid to change direction.Visit the Absolute Gene-ius pageto learn more about the guests, the hosts, and the Applied Biosystems QuantStudio Absolute Q Digital PCR System.
Jerneja Tomsic is a rebellious, outspoken gal (thank goodness) who carries a PhD in Molecular Biology. Being from Slovenia (as is Melania Trump), she knows about socialism... down to the untruths of science paradigms because she is in that world, is now awake and researches. From the lies of PCR tests being effective in diagnosing Co*v*d down to the truth of DNA/double helix, cancer, mammograms, viruses and bacteria.For the "Just Be Practice," Jerneja highlights how fear is the real virus.References for the show:https://viroliegy.comConversation on breast health:https://odysee.com/@Dawn-Lester:3/Conversation-with-Robyn---Jerneja:eLinks to Jerneja:Her Rumble channel: https://rumble.com/user/Jerneja18Chat with Kevin Corbett on PCR tests for The End of COVID project:https://odysee.com/@TheEndOfCovid:3/20230706-TEOC-TEOC-SESSION-The-PCR-Tests--Dr--Jerneja-Tomsic--Dr--Kevin-Corbett-MULTICAM-CUT-2-mov-by-NA:bThe Scientific Method:https://rumble.com/v59dcal-mwk-science-1-the-scientific-method-jerneja-tomsic.htmlPeer Review:https://rumble.com/v5b8wcd-mwk-science-2-peer-review-jerneja-tomsic.html*Host Eden Koz is a soul realignment specialist utilizing such gifts as psychological empathy, intuition, psychic ability, mediumship, meditation, mindset shift, Reiki, dimensional and galactic healing, to name a few. She can also perform a spiritual Co#id Vac+ Healing as well as remote & face-to-face sessions with individuals and groups. Contact info for Eden Koz / Just Be®, LLC:Website: EdenJustBe.com Socials: Insta, FB, FB (Just Be), LinkedIn Just Be~Spiritual BOOM Podcast can be found on the audio directories: Apple Podcasts, Spotify, Amazon Music, Stitcher, iHeart Radio, TuneIn+Alexa, ...
In this episode of Speaking of Mol Bio, Aistė Serapinaite, an experienced R&D scientist, shares her insights into the world of 1-Step RT-PCR—a method that simplifies RNA analysis by combining reverse transcription and PCR amplification in a single reaction. She explains how traditional RNA workflows once lengthy, multi-step processes were prone to errors and contamination, and how 1-Step RT-PCR has transformed this landscape with speed, efficiency, and fewer handling steps.Listeners learn about the technical workings of 1-Step RT-PCR, including the importance of primer design, RNA quality, and essential controls to ensure reliable results. Aistė highlights the Invitrogen SuperScript IV UniPrime One-Step RT-PCR System, emphasizing features like universal annealing temperatures and high sensitivity, capable of detecting even trace levels of RNA.The episode also explores diverse applications, from gene expression studies and cancer biomarker detection to monitoring viral pathogens such as SARS-CoV-2 and Zika virus. While acknowledging the limitations of 1-Step RT-PCR—like the inability to archive cDNA for future assays—Aistė affirms its role as a fast, robust, and eco-friendly solution for high-throughput molecular biology labs. Whether you're new to molecular workflows or an experienced researcher, this episode offers valuable tips and tools to optimize your RNA experiments.Helpful resource links mentioned in this episode:See how one-step RT-PCR is used for amplicon-based viral genome sequencingView a video on the differences between one-step and two-step RT-PCRAccess the Oligo Perfect Primer Designer toolOrder or check out the brochure for Invitrogen SuperScript IV UniPrime One-Step RT-PCR SystemOrder Invitrogen ezDNase Enzyme Subscribe to get future episodes as they drop and if you like what you're hearing we hope you'll share a review or recommend the series to a colleague. Visit the Invitrogen School of Molecular Biology to access helpful molecular biology resources and educational content, and please share this resource with anyone you know working in molecular biology. For Research Use Only. Not for use in diagnostic procedures.
Astăzi sunt prezentate rezultatele complete ale unui sondaj realizat de INSCOP Research împreună cu Institutul de Investigare a Crimelor Comunismului și Memoria Exilului Românesc (IICCMER). Dar, chiar înainte de a vedea toate rezultatele sondajului am aflat câteva date esențiale și anume că 66% din respondenți consideră că Nicolae Ceaușescu a fost „un președinte bun pentru țară”. Ceva mai rău de atât aproape că nu se poate. Anii 2000 au adus nostalgia după regimul comunist. Dar, acum, parcă nu mai este vorba despre nostalgie, ci despre un val mare de simpatie. Deja, societatea românească suferă nu doar de amnezie, de lipsa informațiilor sau de confuzie, ci pare că a intrat într-o altă fază pe care am putea să o numim „amestecul valorilor”. O parte importantă din calificativul „Ceaușescu un președinte bun pentru țară” ține și de economie. Mai exact, de investițiile pe care le-a făcut regimul comunist în perioada 1945-1989. Am avut de-a lungul anilor ocazia să vorbesc cu nostalgici ai regimului Ceaușescu. Mai în vârstă sau, surprinzător, în ultimul timp, tot mai tineri. Este de-a dreptul de neimaginat să găsești tineri care nu erau născuți în anul 1989, absolut îndrăgostiți de regimul comunist sau de Nicolae Ceaușescu. Cu nostalgicii nu o poți scoate niciodată la capăt. Tu le spui de cenzură și de lipsa libertății de exprimare, ei îți răspund că acum ai libertate, dar nu ai bani în buzunar. Ei îți spun că regimul comunist a construit întreprinderi și blocuri pentru oamenii muncii, tu le spui că efortul, inutil de altfel, de a duce datoria externă la zero a degradat nivelul de trai al populației, ei îți spun că Nicolae Ceaușescu a lăsat o țară fără datorii și cu o industrie puternică, tu îi spui că România era dependentă de câteva piețe. În fine, ei îți spun că înainte de anul 1989 fiecare avea un loc de muncă, tu le spui că funcționa metoda PCR, adică pile, cunoștințe, relații. Pe fond, însă, economia de astăzi este cu totul altceva în comparație cu cea dinainte de anul 1989. Acum, România are o economie deschisă, în timp ce înainte de 1989 era o economie închisă, în sensul că era o economie controlată sută la sută de stat. Planificarea mergea până acolo încât prețurile produselor erau stabilite de stat printr-o așa-numită balanță a legăturilor între ramuri. Întreprinderile de stat nu făceau decât să respecte prețurile impuse de Comitetul de Stat al Planificării. Rezultatul a fost că unele întreprinderi au ajuns să aibă pierderi substanțiale. O economie de comandă care a încercat să planifice totul și a sfârșit într-o minciună. De altfel, în ultimii doi ani ai regimului comunist economia a fost în recesiune. Era sfârșitul unui ciclu care a început în anul 1982 cu ideea achitării datoriei externe și care se încheie în anul 1989 cu recesiune și cu plata datoriei în luna martie. Mai sunt multe argumente care arată diferențele de funcționare a economiei înainte și după anul 1989. Economia de comandă era dependentă de sistemul CAER, un tratat economic al fostelor state socialiste. România avea piețe sigure de desfacere în interiorul CAER. Doar că anul 1990 a adus destrămarea sistemului CAER și implicit a piețelor. Marile întreprinderi românești au rămas peste noapte fără piețele de până atunci. Chiar și sistemul intern construit special pentru a exporta mărfuri s-a prăbușit și astfel fiecare firmă de stat a trebuit să înceapă o viață nouă într-o epoca nouă. Cifrele sunt și ele fără dubiu. România a făcut progrese enorme după anul 1989: PIB-ul pe cap de locuitor a crescut de câteva ori, structura economiei s-a modificat radical, salariile au urcat mult, iar cursul de schimb leu-euro a fost relativ stabil. Dar, indiferent cât de multe ar fi evoluțiile pozitive, o parte semnificativă din populație va ofta după comunism. Se poate repara această situație? Cu Nicolae Ceaușescu mort nu te poți lupta, dar fantomele comunismului pot fi risipite.
Amebíase hepática: o diagnóstico que engana até olhos experientes.No episódio nº 149 do InfectoCast, William e João analisam dois casos clínicos reais que escancaram os desafios do diagnóstico da amebíase hepática, uma infecção parasitária que pode imitar hepatite, colangite, neoplasia ou abscesso bacteriano. Quando a cultura vem negativa e o quadro clínico é ambíguo, é o raciocínio infectológico refinado que faz a diferença.Neste episódio, você aprende como construir a suspeita diagnóstica, interpretar exames como PPF, antígeno por ELISA e PCR de fezes, decidir o momento certo de tratar com metronidazol e o que fazer em caso de toxicidade.Também discutimos fatores sociais como saneamento básico precário e como hábitos de vida, deslocamentos e contexto epidemiológico influenciam o diagnóstico.Dá o play e escute o que ninguém te contou sobre amebíase e o que ela exige da sua prática clínica.
Many people struggling with chronic illness, fatigue, brain fog, or unexplained symptoms never find real answers because they're not addressing the root cause: cellular toxicity. In this episode, Dr. Robert Whitfield sits down with Dr. Daniel Pompa, a leading voice in cellular detox and functional medicine, to explore why so many people stay sick despite trying countless protocols. They break down how inflammation, toxic overload, and chemical exposure disrupt your body at the cellular level and what it actually takes to start healing. Whether you're dealing with hormonal imbalances, autoimmune symptoms, or post-explant recovery, this conversation is a must-listen for anyone interested in root-cause healing and natural detox strategies that work.
Stool testing technology has advanced rapidly in recent years, with newer methods like PCR and whole-genome sequencing offering faster and more precise insights into the gut microbiome. These innovations have transformed how clinicians approach gut health, allowing for more targeted interventions. However, older technologies—such as microscopy, culture, and enzyme-based assays—still play a valuable role. These methods provide functional insights that molecular tools may miss, such as direct observation of parasites or assessment of digestive markers. The most comprehensive labs recognize that no single method gives the full picture. Instead, combining the strengths of both modern and traditional techniques ensures more accurate, clinically meaningful results. In this episode, we dive into the pros and cons of different laboratory methodologies used in stool testing—from culture and microscopy to PCR and advanced sequencing. We break down how these choices impact accuracy, sensitivity, and clinical usefulness. You'll also learn why Genova Diagnostics stands out for its integrative, evidence-based approach, combining multiple testing methods to deliver the most comprehensive and clinically actionable results available. Today on The Lab Report: 4:00 Technology grows quickly, and the microbiome is complex 7:30 Microbiology culture 12:40 PCR – very precise if done correctly! 17:00 Interpreting the laundry list 20:10 Remember the microscope? 23:30 Whole-genome (shotgun) sequencing pros/cons 27:15 Genova does it all – and well Additional Resources: GI Effects Stool Profile Microbiomix Subscribe, Rate, & Review The Lab Report Thanks for tuning in to this week’s episode of The Lab Report, presented by Genova Diagnostics, with your hosts Michael Chapman and Patti Devers. If you enjoyed this episode, please hit the subscribe button and give us a rating or leave a review. Don’t forget to visit our website, like us on Facebook, follow us on Twitter, Instagram, and LinkedIn. Email Patti and Michael with your most interesting and pressing questions on functional medicine: podcast@gdx.net. And, be sure to share your favorite Lab Report episodes with your friends and colleagues on social media to help others learn more about Genova and all things related to functional medicine and specialty lab testing. To find a qualified healthcare provider to connect you with Genova testing, or to access select products directly yourself, visit Genova Connect. Disclaimer: The content and information shared in The Lab Report is for educational purposes only and should not be taken as medical advice. The views and opinions expressed in The Lab Report represent the opinions and views of Michael Chapman and Patti Devers and their guests.See omnystudio.com/listener for privacy information.
In today's episode, we had the opportunity to speak with Henry M. Kuerer, MD, PhD, FACS, CMQ, about the potential to safely omit surgery in a subset of patients with early-stage HER2-positive or triple-negative breast cancer who achieve a pathologic complete response (pCR) following neoadjuvant systemic therapy. Dr Kuerer is a professor of breast surgical oncology at The University of Texas MD Anderson Cancer Center in Houston, Texas. In our conversation, Dr Kuerer reviewed the rationale behind a prospective phase 2 clinical trial (NCT02945579) testing image-guided vacuum-assisted core biopsy to identify patients with no residual disease after neoadjuvant therapy. He outlined the strict technical and eligibility criteria that enabled accurate detection of pCR—including tumors downsizing to less than 2 cm and biopsy of at least 12 cores from the tumor bed—and discussed why this biopsy-based approach may be more reliable than standard surgery in detecting residual disease. He also highlighted the broader clinical implications of the findings, noting that patients with biopsy-confirmed pCR may proceed directly to radiotherapy and avoid breast surgery altogether.
01:00:45 – 01:07:03UN-Backed One-World Climate Religion and Indoctrination in SchoolsCoverage details a global initiative to unite religions under environmentalism, replacing Judeo-Christian morality with “common values” aligned to Agenda 2030. Education systems, the Vatican, and the UN are identified as key actors in promoting this shift, with critiques of figures like Pope Francis and references to occultist influences on global spirituality. 01:21:14 – 01:29:28Homeschooling Crackdown and Christian Persecution in ChinaA deep dive into illegal homeschooling under China's communist regime, highlighting a pastor's defiance in educating his children biblically and the risks parents face, including imprisonment and loss of educational access. The narrative contrasts this with U.S. leniency and warns about potential future parallels. 02:07:33 – 02:14:5622 States Support Lawsuit Against School Over Gender Transition Without Parental ConsentA New Jersey father sues after his daughter is socially transitioned by school staff without his knowledge. The case raises questions about state overreach, parental rights, and the ideology embedded in public education, prompting a national coalition of states to intervene. 02:54:24 – 02:55:27Metadata Comparison to Obama's Birth Certificate Sparks Broader DistrustAnalysis of the Epstein footage metadata triggers comparisons to the Obama birth certificate controversy, where layered files were also detected. Critics suggest this pattern of digital tampering exposes a long-standing culture of government deceit and misuse of Adobe tools to fabricate documents. 03:01:38 – 03:04:21Trump Reverses on Epstein Files, Blames Political EnemiesTrump dismisses the Epstein files as fabricated by Democrats, despite having campaigned on releasing them. The narrative is described as a “mutual destruction” scenario implicating both parties, and his sudden shift is portrayed as preemptive damage control amid growing MAGA backlash. 03:06:51 – 03:08:09Epstein-Mossad Theory Reemerges Amid Trump Loyalty CriticismA claim resurfaces that Epstein worked for Israeli intelligence and acquired blackmail material on Trump. The connection is tied to Israeli elites like Ehud Barak and Les Wexner, with allegations that these ties explain Trump's consistent alignment with Israeli interests. 03:39:42 – 03:42:14Charges Dropped Against COVID Vaccine Skeptic Dr. Kirk MooreAttorney General Pam Bondi orders charges dismissed against Dr. Kirk Moore, who was accused of issuing fake COVID vaccine cards and destroying doses. The move is portrayed as a political concession to the MAGA base, with criticism of the government's original crackdown and praise for Moore's resistance to mandates. 03:56:19 – 03:57:09Push to Remove Vaccine Liability Protections and Enable LawsuitsAdvocates urge lawmakers to revoke immunity protections for vaccine makers and reclassify mRNA injections as gene-altering. The segment calls for retroactive lawsuits, arguing that only direct legal consequences will halt corporate harm. 03:57:47 – 03:58:32COVID Measures Blamed for More Harm Than Virus ItselfClaims are made that the "cure"—vaccines, ventilators, and Remdesivir—caused more deaths than COVID. The PCR test is mocked as unreliable, and the segment portrays pandemic policy as a coordinated scam by the healthcare system. Follow the show on Kick and watch live every weekday 9:00am EST – 12:00pm EST https://kick.com/davidknightshow Money should have intrinsic value AND transactional privacy: Go to https://davidknight.gold/ for great deals on physical gold/silverFor 10% off Gerald Celente's prescient Trends Journal, go to https://trendsjournal.com/ and enter the code KNIGHTFind out more about the show and where you can watch it at TheDavidKnightShow.comIf you would like to support the show and our family please consider subscribing monthly here: SubscribeStar https://www.subscribestar.com/the-david-knight-showOr you can send a donation throughMail: David Knight POB 994 Kodak, TN 37764Zelle: @DavidKnightShow@protonmail.comCash App at: $davidknightshowBTC to: bc1qkuec29hkuye4xse9unh7nptvu3y9qmv24vanh7Become a supporter of this podcast: https://www.spreaker.com/podcast/the-david-knight-show--2653468/support.
01:00:45 – 01:07:03UN-Backed One-World Climate Religion and Indoctrination in SchoolsCoverage details a global initiative to unite religions under environmentalism, replacing Judeo-Christian morality with “common values” aligned to Agenda 2030. Education systems, the Vatican, and the UN are identified as key actors in promoting this shift, with critiques of figures like Pope Francis and references to occultist influences on global spirituality. 01:21:14 – 01:29:28Homeschooling Crackdown and Christian Persecution in ChinaA deep dive into illegal homeschooling under China's communist regime, highlighting a pastor's defiance in educating his children biblically and the risks parents face, including imprisonment and loss of educational access. The narrative contrasts this with U.S. leniency and warns about potential future parallels. 02:07:33 – 02:14:5622 States Support Lawsuit Against School Over Gender Transition Without Parental ConsentA New Jersey father sues after his daughter is socially transitioned by school staff without his knowledge. The case raises questions about state overreach, parental rights, and the ideology embedded in public education, prompting a national coalition of states to intervene. 02:54:24 – 02:55:27Metadata Comparison to Obama's Birth Certificate Sparks Broader DistrustAnalysis of the Epstein footage metadata triggers comparisons to the Obama birth certificate controversy, where layered files were also detected. Critics suggest this pattern of digital tampering exposes a long-standing culture of government deceit and misuse of Adobe tools to fabricate documents. 03:01:38 – 03:04:21Trump Reverses on Epstein Files, Blames Political EnemiesTrump dismisses the Epstein files as fabricated by Democrats, despite having campaigned on releasing them. The narrative is described as a “mutual destruction” scenario implicating both parties, and his sudden shift is portrayed as preemptive damage control amid growing MAGA backlash. 03:06:51 – 03:08:09Epstein-Mossad Theory Reemerges Amid Trump Loyalty CriticismA claim resurfaces that Epstein worked for Israeli intelligence and acquired blackmail material on Trump. The connection is tied to Israeli elites like Ehud Barak and Les Wexner, with allegations that these ties explain Trump's consistent alignment with Israeli interests. 03:39:42 – 03:42:14Charges Dropped Against COVID Vaccine Skeptic Dr. Kirk MooreAttorney General Pam Bondi orders charges dismissed against Dr. Kirk Moore, who was accused of issuing fake COVID vaccine cards and destroying doses. The move is portrayed as a political concession to the MAGA base, with criticism of the government's original crackdown and praise for Moore's resistance to mandates. 03:56:19 – 03:57:09Push to Remove Vaccine Liability Protections and Enable LawsuitsAdvocates urge lawmakers to revoke immunity protections for vaccine makers and reclassify mRNA injections as gene-altering. The segment calls for retroactive lawsuits, arguing that only direct legal consequences will halt corporate harm. 03:57:47 – 03:58:32COVID Measures Blamed for More Harm Than Virus ItselfClaims are made that the "cure"—vaccines, ventilators, and Remdesivir—caused more deaths than COVID. The PCR test is mocked as unreliable, and the segment portrays pandemic policy as a coordinated scam by the healthcare system. Follow the show on Kick and watch live every weekday 9:00am EST – 12:00pm EST https://kick.com/davidknightshow Money should have intrinsic value AND transactional privacy: Go to https://davidknight.gold/ for great deals on physical gold/silverFor 10% off Gerald Celente's prescient Trends Journal, go to https://trendsjournal.com/ and enter the code KNIGHTFind out more about the show and where you can watch it at TheDavidKnightShow.comIf you would like to support the show and our family please consider subscribing monthly here: SubscribeStar https://www.subscribestar.com/the-david-knight-showOr you can send a donation throughMail: David Knight POB 994 Kodak, TN 37764Zelle: @DavidKnightShow@protonmail.comCash App at: $davidknightshowBTC to: bc1qkuec29hkuye4xse9unh7nptvu3y9qmv24vanh7Become a supporter of this podcast: https://www.spreaker.com/podcast/the-real-david-knight-show--5282736/support.
Having met at the UC Davis Wine Executive Program, Kia Behnia, CEO, and Mason Earles, CTO, founded Scout to replicate the best sensor in the vineyard, “the farmer's eye.” Leveraging off-the-shelf hardware, Scout uses AI to process images taken from a tractor to automate vineyard mapping, vine counting, yield forecasting, virus identification, and more. From managing vineyard assets to implementing precision agriculture to improve quality, Scout is harnessing the power of AI to optimize vineyard management.Detailed Show Notes: Mason's background - UC Davis Professor, Apple, AI & agricultureKia's background for Scout - owns the Neotempo wine brand, worked at Splunk, the “data for everything” companyThe official company name is Agricultural Scout, dba Scout, the website is agscout.ai, so it can be called any of those namesFounded in 2022, initially more hardware-based, but pivoted to an intelligence company using off-the-shelf hardwareThe goal is to “replicate the farmer's eye” with an AI-based solution using cameras, tractors, and Scout cloud and mobile app (which can be used offline); the brain is centered around a phoneUS only today (~50-100 clients, 300 blocks, 2M vines, processed 56M photos), going international in 20264 main use cases currently: Automate vine count, inventory, and mapping of vines - 4x faster than people could doEstimate crop performance - both vigor and fruitYield forecasting - can use every step in the growing season to forecast yield with historical performance and weather forecastsHealth performance and vine mapping - leveraging AI for virus detection3 types of clientsEstate wineriesVineyard management companies (“VMC”)Real estate investors or owners to track vineyardsBenefits include: $400-1,200 savings/acreProductivity gains through managing more acres with fewer people, identifying low-performing vines, and the program tells farmers where to sampleRemote monitoring of faraway vineyardsEarly season yield forecastingDisease management - virus can cause $170k/acre damage over 3-5 years, costs $40/PCR test, the goal is to keep virus 50 acresNeighborhood and AVA discountsStarter - 2 scan package (for inventory and virus)Professional - 6 scan packageTypical customer starts w/ 2 and upgrades to 6Monarch promotion, customers get 1 free scanUp front hardware costs ~$3,000New product in beta in July 2025 - ChatGPT Scout for vineyardsMarketing mostly through word of mouth, industry trade shows, and webinars have been effective, as has partnership with Monarch (already tech enthusiasts)Barriers to purchase are often due to farming budgets built around labor Hosted on Acast. See acast.com/privacy for more information.
Chagas disease is a dangerous tropical illness caused by single-cell parasites known as Trypanosoma cruzi. In most cases, if not treated immediately, the infection becomes chronic: the immune system of the host greatly reduces the number of parasites present in the body yet fails to fully eradicate them. Current diagnostic approaches often fail to detect these low numbers of parasites. A research team from the University of Georgia and others aimed to develop a test for cure. Joining me today is Rick Tarleton, PhD. Dr Tarleton ia a Regents' Professor at the University of Georgia and a Distinguished Professor in Biological Sciences in the Department of Cellular Biology. Serial ‘deep-sampling' PCR of fragmented DNA reveals the wide range of Trypanosoma cruzi burden among chronically infected human, macaque, and canine hosts, and allows accurate monitoring of parasite load following treatment
From the archives: 6-21-23Touch DNA refers to the trace amounts of DNA that can be transferred through direct contact between an individual's skin cells and an object or surface. It is a valuable forensic tool used in crime scene investigations to help identify potential suspects or link individuals to a particular location.When individuals touch an object or surface, they leave behind skin cells containing their DNA. Touch DNA analysis involves collecting and analyzing these minute samples to extract the DNA and generate a DNA profile. The DNA profile contains unique genetic markers that can be compared to known DNA samples, such as those from a suspect or a DNA database, to determine a potential match or identify an unknown individual.The process of touch DNA analysis typically involves the following steps:Sample collection: Forensic investigators collect potential touch DNA samples from objects or surfaces at a crime scene using various techniques. This may involve swabbing the surface with a sterile cotton swab or using adhesive tape to lift any visible or invisible biological material.DNA extraction: The collected samples undergo a DNA extraction process to isolate the DNA from other substances present on the surface. This step aims to purify the DNA and remove any potential inhibitors that might interfere with subsequent analysis.DNA amplification: The extracted DNA is subjected to a process called polymerase chain reaction (PCR), which amplifies specific regions of the DNA. PCR allows for the generation of sufficient DNA material for further analysis, even if only a minimal amount of touch DNA was initially present.DNA profiling: The amplified DNA is analyzed using techniques such as short tandem repeat (STR) analysis. STR markers are specific regions within the DNA that exhibit variations in the number of repeated DNA sequences. By comparing the lengths of these STR markers between the crime scene sample and a reference sample, a DNA profile is generated.Database search and interpretation: The DNA profile obtained from the touch DNA sample can be compared to known reference samples from suspects or individuals in a DNA database. If a match is found, it can provide investigative leads or potentially establish a link between the individual and the crime scene.It's important to note that touch DNA analysis has certain limitations. The amount of DNA left behind through touch is often very small, making it susceptible to contamination and degradation. Factors such as the environmental conditions and the time elapsed since the DNA was deposited can affect the quality and quantity of the touch DNA sample. Additionally, the presence of multiple individuals' DNA on an object or surface can complicate the analysis.Nevertheless, touch DNA analysis has proven valuable in numerous criminal investigations, aiding in the identification of suspects, establishing links between individuals and crime scenes, and exonerating innocent individuals. It is a powerful tool in forensic science that complements other methods of DNA analysis, such as blood or saliva DNA samples."The comparison showed a statistical match—specifically, the STR profile is at least 5.37 octillion times more likely to be seen if Defendant is the source than if an unrelated individual randomly selected from the population is the source," the filing says according to the article.In this episode we take a look at how strong that evidence is and how Kohberger's team might attempt to challenge it.(commercial at 7:40)to contact me:bobbycapucci@protonmail.comsource:Bryan Kohberger DNA Revelation Made in New Court Documents (newsweek.com)Become a supporter of this podcast: https://www.spreaker.com/podcast/the-moscow-murders-and-more--5852883/support.
Two Onc Docs, hosted by Samantha A. Armstrong, MD, and Karine Tawagi, MD, is a podcast dedicated to providing current and future oncologists and hematologists with the knowledge they need to ace their boards and deliver quality patient care. Dr Armstrong is a hematologist/oncologist and assistant professor of clinical medicine at Indiana University Health in Indianapolis. Dr Tawagi is a hematologist/oncologist and assistant professor of clinical medicine at the University of Illinois in Chicago. In this episode, OncLive On Air® partnered with Two Onc Docs to bring a discussion of key data from the phase 3 MATTERHORN trial (NCT04592913), which were presented at the 2025 ASCO Annual Meeting. MATTERHORN was a randomized, double-blind, multinational study evaluating the addition of durvalumab (Imfinzi) to FLOT (5-fluorouracil, leucovorin, oxaliplatin, and docetaxel) in patients with previously untreated, resectable gastric or gastroesophageal junction adenocarcinoma. In the MATTERHORN trial, 948 patients were randomly assigned 1:1 to receive either durvalumab or placebo in combination with perioperative FLOT, followed by 10 cycles of durvalumab or placebo as adjuvant therapy. The primary end point was event-free survival (EFS); secondary end points included overall survival (OS) and pathological complete response (pCR). The trial met its primary end point. Durvalumab plus FLOT (n = 474) significantly improved EFS vs placebo plus FLOT (n = 474; HR, 0.71; 95% CI, 0.58-0.86; P < .001), representing a 29% reduction in risk of progression, recurrence, or death. The interim OS analysis showed a nonsignificant trend favoring durvalumab (HR, 0.78; 95% CI, 0.62-0.97; P = .025). The pCR rate was 19% (95% CI, 15.75%-23.04%) with durvalumab vs 7.2% (95% CI, 5.02%-9.88%) with placebo. Toxicity profiles were comparable between the 2 groups, though immune-related adverse effects were more frequent with durvalumab. Importantly, the addition of durvalumab did not delay surgery or initiation of adjuvant therapy. Although the MATTERHORN regimen is not yet FDA approved or included in the National Comprehensive Cancer Network guidelines, this trial demonstrates a promising EFS benefit and potential practice-changing implications, pending mature OS data and further molecular subgroup analyses, according to Armstrong and Tawagi.
With over two decades of experience in the skincare and beauty industry, Tara specializes in building brands that move culture. Her work lives at the intersection of science, storytelling, and soul, and it is always anchored in results.She specializes in grit. Her dad is a third-generation pistachio grower in California, and that blend of artful curiosity, beauty, and serious hard work runs deep in her DNA. Today, as the Global President of Dermatological Skincare at Galderma (Cetaphil, Differin, Alastin, Benzac), she brings that same grounded tenacity to leading a portfolio of globally loved brands. She focuses on driving impact through innovation, advocacy, and breakthrough marketing.A California native now living in Switzerland, after a few unforgettable years in Paris, she brings a global perspective to brand-building. Her approach blends sharp market insight with emotional nuance and deep respect for local culture.She works closely with healthcare professionals to deliver superior outcomes that build trust, create value, and honor the deeply personal nature of skincare. Before joining Galderma, she led transformative work at iconic companies including Kendo Brands (LVMH), Too Faced, and Pierre Fabre, launching breakthrough campaigns and fueling growth across global markets.At her core, she is a builder. She thrives on mentoring future change makers, fostering collaboration, and creating bold, lasting brand value through curiosity, clarity, and purpose.She is also a frequent speaker and podcast guest, passionate about sharing insights on beauty, leadership, and brand-building at the intersection of science and soul.Val Vacante is an award-winning, creative catalyst and global innovator. As the SVP of Solutions Innovation at Dentsu, she uncovers cultural trends, commerce dynamics, and emerging technologies to shape next-generation product innovations, and solutions impacting the way people connect in the physical and digital world.Val is the product lead and innovator behind the Meta Global Messaging Alliance and Intelligent Messaging, Dentsu's first-of-its-kind full suite of end-to-end messaging innovations designed to accelerate 1:1 conversational messaging, AI-amplified assistance, and human connection – showcased at CES, SXSW, Cosmoprofs and featured in Digiday, MediaPost, Retail Brew and more.She is the co-creator behind Dentsu NXT Space, a co-space for rapidly realizing the future of AI, 3D spatial environments, and everyday technology in collaboration with Microsoft, LinkedIn and HeadOffice.space featured in PSFK's, “Best of CES,” Forbes, Fast Company, Digiday, Coindesk and more.Val is also the co-creator of ShopNXT™ — Dentsu's retail innovations focused on helping brands create more personalized shopping experiences increasing loyalty, sales, and customer joy. The ShopNXT suite of products has been named top product picks at CES by PCR Magazine featured in CNET, The Drum, PSFK, eMarketer, MediaPost, PCR among others.Additionally, Val architected and launched NXT Intelligence™ an innovation platform featuring 12 technology, innovation, and brand solutions designed to rapidly explore, evaluate and evolve business growth opportunities. Her latest work focuses on connected experiences, emerging technologies, gaming, retail and play.She is also the Founder of the strategy and innovation firm Collabsco; where she pioneered award-winning digital products and connected experiences across IoT, AR, VR, voice, robotics, and the first connected play landscape featured in VentureBeat, The Drum, VRScout, and more.Her portfolio includes over 50+ brands including Microsoft, Hasbro, Mattel, Disney, Bandai Namco Entertainment, PepsiCo, P&G, Nestlé, Mercedes-Benz, MINI, Galderma, AT&T, Vodafone, Honeywell, Sleep Number, Dell, MERGE, WowWee and Virsix Games, among others.Val has been named one of the Top 25 Women in Tech by PCR magazine and Women in Tech Global Product Management Leader of the Year.
I'm never excited when I diagnose a cat with anaemia: vague signs, confusing diagnostics, and what feels like a not-so-great prognoses. But are they really that hopeless?In this episode, feline medicine specialist Dr Rachel Korman joins us demystify the anaemic cat and offer a clear, practical diagnostic framework that will give you more confidence and better outcomes the next time you see a cat with a low PCV.Some highlights from this conversation:A step-by-step approach to categorising anaemia.Regenerative vs. non-regenerative: what it actually means in cats, and how to interpret the data.Why IMHA in cats doesn't look like IMHA in dogs — and how to recognise it.Haemoplasma infections (like Mycoplasma): When to treat, how to treat, PCR testing, and what the results really tell you.Age-specific differentials: what to prioritise in young vs. older cats.Supportive care: what works, what's myth.Prognosis pitfalls: why PCV alone doesn't predict survival.This episode will help you approach feline anaemia with more clarity, structure, and - dare we say - optimism.
Join The Beyond Terrain Community:https://beyond-terrain.circle.so/join?invitation_token=08c95fc3df8ff802b3bd05091df70e5a7bf0f297-2ceb428c-0b15-4d16-be23-81d5a8adb098Links:Previous Podcast on PCR: https://youtu.be/UiJLzEjOH1gBlog Post: https://criticalcheck.wordpress.com/2021/12/15/dna-discovery-extraction-and-structure-a-critical-review/DNA Images: https://pubs.acs.org/doi/10.1021/nl3039162In this bold and paradigm-shifting episode, Dr. Jerneja Tomsic returns to question one of the most foundational pillars of modern biology: DNA itself.We begin with the core question—why are we questioning DNA?—and move into the assumptions behind DNA extraction, its structure, and supposed stability. Dr. Tomsic breaks down the flaws in the methods used to "discover" and analyze DNA, exposing how much of the field is built on chemical manipulation, indirect inference, and unobservable constructs.We explore the problems embedded in DNA science—from experimental artifacts to the theoretical nature of gene function—and ask whether the genetic model has become more dogma than discovery.This is not just a critique of molecular biology—it's an invitation to reclaim scientific rigor and rethink life from the ground up. A must-listen for anyone ready to challenge sacred cows in science.Keep up with me (socials)https://www.instagram.com/beyond.terrain/https://beyondterrain.com/Our vision at Beyond Terrain is greatly supported by sharing our work!Become a Founding Member in the community!https://beyond-terrain.circle.so/checkout/founding-memberLearn more from and support our esteemed guest, Dr. Tomsichttps://x.com/zianiniSLO
What's the best gift you can give? To the millions of people whose lives have been saved by complete strangers, the answer would be simple: blood. But what exactly happens when blood has been donated, and how do we know it is safe? We chat to Dr Richard Mayne from Oxford's Experimental Medicine Division about genomics, Next-Generation Sequencing, blood screening (...and Star Trek). Could you be a blood-donating hero? Blood stocks are currently critically low, with the NHS Blood and Transplant (NHSBT) group in urgent need of new donors. Click here, and you'll be on your way to saving lives: https://www.blood.co.uk/news-and-campaigns/campaigns/blood-donor-appeal/
In this Mol Bio Minutes episode, Laurynas Alijošius shares a personal story that every molecular biologist can relate to—running PCR, cloning, and sequencing, only to discover frustrating errors in the DNA. This episode dives deep into PCR accuracy and why it matters for everything from sequencing to cloning and long-read library prep. Laurynas breaks down the major contributors to PCR error, including the fidelity of DNA polymerase, primer design flaws, template impurities, and suboptimal cycling conditions. He then offers a range of solutions—like switching to high-fidelity enzymes, using ready-to-go master mixes, and optimizing magnesium ion concentrations. He also explains how reducing cycle numbers and fine-tuning annealing temperatures can minimize unwanted amplification and ensure more reliable data.Whether you're troubleshooting or proactively optimizing your workflow, this episode is packed with tips and tools to help you increase PCR accuracy, reduce costs, and save time. Episode notes contain links to enzyme comparisons, primer design tools, and cycling guides to help you PCR with precision.Helpful resource links mentioned in this episode:Thermo Scientific web tools for primer design and analysis, and moreThe PCR Learning Center with lots of helpful tips and informationLearn more about PCR reagents and enzymesBrowse and purchase PCR enzymes and master mixesAccess the PCR troubleshooting guideDownload the molecular biology handbook Subscribe to get future episodes as they drop and if you like what you're hearing we hope you'll share a review or recommend the series to a colleague. Visit the Invitrogen School of Molecular Biology to access helpful molecular biology resources and educational content, and please share this resource with anyone you know working in molecular biology. For Research Use Only. Not for use in diagnostic procedures.
Dr. Allison Zibelli and Dr. Rebecca Shatsky discuss advances in breast cancer research that were presented at the 2025 ASCO Annual Meeting, including a potential new standard of care for HER2+ breast cancer, the future of ER+ breast cancer management, and innovations in triple negative breast cancer therapy. Transcript Dr. Allison Zibelli: Hello and welcome to the ASCO Daily News Podcast. I'm Dr. Allison Zibelli, your guest host of the podcast today. I'm an associate professor of medicine and a breast medical oncologist at the Sidney Kimmel Comprehensive Cancer Center at Jefferson Health. There was a substantial amount of exciting breast cancer data presented at the 2025 ASCO Annual Meeting, and I'm delighted to be joined by Dr. Rebecca Shatsky today to discuss some of these key advancements. Dr. Shatsky is an associate professor of medicine at UC San Diego and the head of breast medical oncology at the UC San Diego Health Moores Cancer Center, where she also serves as the director of the Breast Cancer Clinical Trials Program and the Inflammatory and Triple-Negative Breast Cancer Program. Our full disclosures are available in the transcript of this episode. Dr. Shatsky, it's great to have you on the podcast today. Dr. Rebecca Shatsky: Thanks, Dr. Zibelli. It's wonderful to be here. Dr. Allison Zibelli: So, we're starting with DESTINY-Breast09, which was trastuzumab deruxtecan and pertuzumab versus our more standard regimen of taxane, trastuzumab pertuzumab for first-line treatment of metastatic HER2-positive breast cancer. Could you tell us a little bit about the study? Dr. Rebecca Shatsky: Yeah, absolutely. So, this was a long-awaited study. When T-DXd, or trastuzumab deruxtecan, really hit the market, a lot of these DESTINY-Breast trials were started around the same time. Now, this was a global, randomized, phase 3 study presented by Dr. Sara Tolaney from the Dana-Farber Cancer Institute of Harvard in Boston. It was assessing essentially T-DXd in the first-line setting for metastatic HER2-positive breast cancer in addition to pertuzumab. And that was randomized against our standard-of-care regimen, which was established over a decade ago by the CLEOPATRA trial, and we've all been using that internationally for at least the past 10 years. So, this was a large trial, and it was one-to-one-to-one of patients getting T-DXd plus pertuzumab, T-DXd alone, or THP, which mostly is used as docetaxel and trastuzumab and pertuzumab every three weeks for six cycles. And this was in over 1,000 patients; it was 1,159 patients with metastatic HER2-positive breast cancer. This was a very interesting trial. It was looking at the use of trastuzumab deruxtecan, but patients were started on this treatment for their first-line metastatic HER2-positive breast cancer with no end date to their T-DXd. So, it was, you know, you were started on T-DXd every 3 weeks until progression. Now, CLEOPATRA is a little bit different than that, though, as we know. So, CLEOPATRA has a taxane plus trastuzumab and pertuzumab. But generally, patients drop the taxane after about six to seven cycles because, as we know, you can't be really on a taxane indefinitely. You get pretty substantial neuropathy as well as cytopenias, other things that end up happening. And so, in general, that regimen has sort of a limited time course for its chemotherapy portion, and the patients maintained after the taxane is dropped on their trastuzumab and their pertuzumab, plus or minus endocrine therapy if the investigator so desires. And the primary endpoint of the trial was progression-free survival by blinded, independent central review (BICR) in the intent-to-treat population. And then it had its other endpoints as overall survival, investigator-assessed progression-free survival, objective response rates, and duration of response, and of course, safety. As far as the results of this trial, so, I think that most of us key opinion leaders in breast oncology were expecting that this was going to be a positive trial. And it surely was. I mean, this is a really, really active drug, especially in HER2-positive disease, of course. So, the DESTINY-Breast03 data really established that, that this is a very effective treatment in HER2-positive metastatic breast cancer. And this trial really, again, showed that. So, there were 383 patients that ended up on the trastuzumab plus deruxtecan plus pertuzumab arm, and 387 got THP, the CLEOPATRA regimen. What was really interesting also to note of this before I go on to the results was that 52% of patients on this trial had de novo metastatic disease. And that's pretty unusual for any kind of metastatic breast cancer trial. It kind of shows you, though, just how aggressive this disease is, that a lot of patients, they present with de novo metastatic disease. It's also reflecting the global nature of this trial where maybe the screening efforts are a little bit less than maybe in the United States, and more patients are presenting as later stage because to have a metastatic breast cancer trial in the United States with 52% de novo metastatic disease doesn't usually happen. But regardless, the disease characteristics were pretty well matched between the two groups. 54% of the patients were triple positive, or you could say hormone-positive because whether they were PR positive or ER positive and PR negative doesn't really matter in this disease. And so, the interim data cutoff was February of this year, of 2025. So, the follow-up so far has been about 29 months, so the data is still really immature, only 38% mature for progression-free survival interim analysis. But what we saw is that T-DXd plus pertuzumab, it really improved progression-free survival. It had a hazard ratio that was pretty phenomenal at 0.56 with a confidence interval that was pretty narrow of 0.44 to 0.71. So, very highly statistically significant data here. The progression-free survival was consistent across all subgroups. Overall survival, very much immature at this time, but of course, the trend is towards an overall survival benefit for the T-DXd group. The median durable response with T-DXd plus pertuzumab exceeded 3 years. Now, importantly, though, I want to stress this, is grade 3 or above treatment-emergent adverse events occurred in both subgroups pretty equally. But there were 2 deaths in the T-DXd group due to interstitial lung disease. And there was a 12.1% adjudicated drug-induced interstitial lung disease/pneumonitis event rate in the T-DXd group and only 1%, and it was grade 1-2, in the THP group. So, that's really the caveat of this therapy, is we know that a percentage of patients are going to get interstitial lung disease, and that some may have very serious adverse events from it. So, that's always something I keep in the back of my mind when I treat patients with T-DXd. And so, overall, the conclusions of the trial were pretty much a slam dunk. T-DXd plus pertuzumab, it had a highly statistically significant and clinically meaningful improvement in progression-free survival versus the CLEOPATRA regimen. And that was across all subgroups for first-line metastatic HER2-positive breast cancer here. And so, yeah, the data was pretty impressive. Just to go into the overall response rate, because that's always super important as well, you had 85.1% of patients having a confirmed overall RECIST response rate in the T-DXd plus pertuzumab group and a 78.6 in the CLEOPATRA group. The complete CR rate, complete response was 15.1% in the T-DXd group and 8.5 in the CLEOPATRA regimen. And it was really an effective regimen in this group, of course. Dr. Allison Zibelli: So, the investigators say at the end of their abstract that this is the new standard of care. Would you agree with that statement? Dr. Rebecca Shatsky: Yeah, that was a bold statement to make because I would say in the United States, not necessarily at the moment because the quality of life here, you have to think really hard about. Because one thing that's really important about the DESTINY-Breast09 data is that this was very much an international trial, and in many of the countries where patients enrolled on this, they were not able to access T-DXd off trial. And so, for them, this means T-DXd now or potentially never. And so, that is a really big difference whereas internationally, that may mean standard of care. However, in the US, patients have no issues accessing T-DXd in the second- or third-line settings. And right now, it's the standard of care in the second line in the United States, with all patients basically getting this second-line therapy except for some unique patients where they may be doing a PATINA trial regimen, which we saw at San Antonio Breast Cancer in 2024 of the triple-positive patients getting hormonal therapy plus palbociclib, which had a really great durable response. That was super impressive as well. Or there is the patient that the investigator can pick KADCYLA because the patient really wants to preserve their hair or maybe it's more indolent disease. But the quality of life on T-DXd indefinitely in the first-line setting is a big deal because, again, that CLEOPATRA regimen allows patients to drop their chemotherapy component about five to six months in. And with this, you're on a drug that feels very chemo-heavy indefinitely. And so, I think there's a lot more to investigate as far as what we're going to do with this data in the United States because it's a lot to commit a patient in the first-line metastatic setting. These de novo metastatic patients, some of them may be cured, honestly, on the HER2-targeting regimen. That's something we see these days. Dr. Allison Zibelli: So, very interesting trial. I'm sure we'll be talking about this for a long time. So, let's move on to SERENA-6, which was, I thought, a very interesting trial. This trial took patients with ER positive, advanced breast cancer after six months on an AI (aromatase inhibitor) and a CDK4/6 inhibitor. They did ctDNA every two to three months, and when they saw an ESR1 mutation emerge, they changed half of the patients to camizestrant plus CDK4/6 and kept the other half on the AI plus CDK4/6. Can you talk about that trial a little bit, please? Dr. Rebecca Shatsky: Yeah, so this was a big trial at ASCO25. This was presented as a Plenary Session. So, this was camizestrant plus a CDK4/6 inhibitor, and it could have been any of the three, so palbo, ribo, or abemaciclib in the first-line metastatic hormone-positive population, and patients were on an AI with that. They were, interestingly, tested by ctDNA at baseline to see if they had an ESR1 mutation. So, that was an interesting feature of this trial. But patients had to have already been on their CDK4/6 inhibitor plus AI for at least 6 months to enroll. And then, as you mentioned, they got ctDNA testing every 2 to 3 months. This was also a phase 3, double-blind, international trial. And I do want to highlight again, international here, because that's important when we're considering some of this data in the U.S. because it influences some of the results. So, this was presented by Dr. Nick Turner of the Royal Marsden in the UK. So, just a little bit of background for our listeners on ESR1 mutations and why they're important. This is the most common, basically, acquired resistance mutation to patients being treated with aromatase inhibitors. We know that treatment with aromatase inhibitors can induce this. It makes a conformational change in the estrogen receptor that makes the estrogen receptor constitutively active, which allows the cell to signal despite the influence of the aromatase inhibitor to decrease the estrogen production so that the ligand binding doesn't matter as much as far as the cell signaling and transcription is concerned. And camizestrant, you know, as an oral SERD, just to explain that a little bit too; these are estrogen receptor degraders. The first-in-class of a selective estrogen receptor degrader to make it to market was fulvestrant. And that's really been our standard-of-care estrogen degrader for the past 25 years, almost 25 years. And so, a lot of us are just looking for some of these oral SERDs to replace that. But regardless, they do tend to work in the ESR1-mutated population. And we know that patients on aromatase inhibitors, the estimates of patients developing an ESR1 mutation, depending on which study you look at, somewhere between 30% to 50% overall, patients will develop this mutation with hormone-positive metastatic breast cancer. There is a small percentage of patients that have these at baseline without even treatment of an aromatase inhibitor. The estimates of that are somewhere between 0.5 and up to 5%, depending on the trial you look at and the population. But regardless, there is a chance someone on their CDK4/6 inhibitor plus AI at 6 months' time course could have had an ESR1 mutation at that time. But anyway, so they got this ctDNA every 2 to 3 months, and once they were found to develop an ESR1 mutation, the patients were then switched to the oral SERD. AstraZeneca's version of the oral SERD is camizestrant, 75 mg daily. And then their type of CDK4/6 inhibitor was maintained, so they didn't switch the brand of their CDK4/6 inhibitor, importantly. And that was looked at then for progression-free survival, but these were patients with measurable disease by RECIST version 1.1. And the data cut off here was November of 2024. This was a big trial, you know, and I think that that's influential here because this was 3,256 patients, and that's a lot of patients. So, they were all eligible. And then 315 patients ended up being randomized to switch to camizestrant upon presence of that ESR1 mutation. So, that was 157 patients. And then the other half, so they were randomized 1:1, they continued on their AI without switching to an oral SERD. That was 158 patients. They were matched pretty well. And so, their baseline characteristics, you know, the two subgroups was good. But this was highly statistically significant data. I'm not going to diminish that in any way. Your hazard ratio was 0.44. Highly statistically significant confidence intervals. And you had a median progression-free survival in those that switched to camizestrant of 16 months, and then the non-switchers was 9.2 months. So, the progression-free survival benefit there was also consistent across the subgroups. And so, you had at 12 months, the PFS rate was 60.7% for the non-treatment group and 33.4% in the treatment group. What's interesting, though, is we don't have overall survival data. This is really immature, only 12% mature as far as overall survival. And again, because this was an international trial and patients in other countries right now do not have the access to oral SERDs that the United States does, the crossover rate, they were not allowed to crossover, and so, a very few patients, when we look at progression-free survival 2 and ultimately overall survival, were able to access an oral SERD in the off-trial here and in the non-treatment group. And so, that's really important as far as we look at these results. Adverse events were pretty minimal. These are very safe drugs, camizestrant and all the other oral SERDs. They have some mild toxicities. Camizestrant is known for something weird, which is called photopsia, which is some flashing lights in the periphery of the eye, but it doesn't seem to have any serious clinical significance that we know of. It has a little bit of bradycardia, but it's otherwise really well tolerated. You know, I hate to say that because that's very subjective, right? I'm not the one taking the drug. But it doesn't have any serious adverse events that would cause discontinuation. And that's really what we saw in the trial. The discontinuation rates were really low. But overall, I mean, this was a positive trial. SERENA-6 showed that switching to camizestrant at the first sign of an ESR1 mutation on CDK4/6 inhibitor plus AI improved progression-free survival. That's all we can really say from it right now. Dr. Allison Zibelli: So, let's move on to ASCENT-04, which was a bit more straightforward. Sacituzumab govitecan plus pembrolizumab versus chemotherapy plus pembrolizumab in PD-L1-positive, triple-negative breast cancer. Could you talk about that study? Dr. Rebecca Shatsky: Yeah, so this was also presented by the lovely Sara Tolaney from Dana-Farber. And this study made me really excited. And maybe that's because I'm a triple-negative breast cancer person. I mean, not to say that I don't treat hundreds of patients with hormone- positive, but our unmet needs in triple negative are huge because this is a disease where you have got to throw your best available therapy at it as soon as you can to improve survival because survival is so poor in this disease. The average survival with metastatic triple-negative breast cancer in the United States is still 13-18 months, and that's terrible. And so, for full disclosure, I did have this trial open at my site. I was one of the site PIs. I'm not the global PI of the study, obviously. So, what this study was was for patients who had had at least a progression-free survival of 6 months after their curative intent therapy or de novo metastatic disease. They were PD-L1 positive as assessed by the Dako 22C3 assay of greater than or equal to a CPS score of 10. So, that's what the KEYNOTE-355 trial was based on as well. So, standard definition of PD-L1 positive in breast cancer here. And basically, these patients were randomized 1:1 to either their sacituzumab govitecan plus pembrolizumab, day 1 they got both therapies, and then day 8 just the saci, as is standard for sacituzumab. And then the other group got the KEYNOTE-355 regimen. So, that is pembrolizumab with – your options are carbogem there, paclitaxel or nab-paclitaxel. And it's up to investigator's decision which upon those they decided. They followed these patients for disease progression or unacceptable toxicity. It was really an impressive trial in my opinion because we know already that this didn't just improve progression-free survival, because survival is so poor in this disease, of course, we know that it improved overall survival. It's trending towards that very much, and I think that's going to be shown immediately. And then the objective response rates were better, which is key in this disease because in the first-line setting, you've got a lot of people who, especially your relapsed TNBC that don't respond to anything. And you lose a ton of patients even in the first-line setting in this disease. And so, this was 222 patients to chemotherapy and pembro and 221 to sacituzumab plus pembro. Median follow-up has only been 14 months, so it's still super early here. Hazard ratio so far of progression-free survival is 0.65, highly statistically significant, narrow confidence intervals. And so, the median duration of response here for the saci group was 16.5 months versus 9.2 months. So, you're getting a 7-month progression-free survival benefit here, which in triple negative is pretty fantastic. I mean, this reminds me of when we saw the ASCENT data originally come out for sacituzumab, and we were all just so happy that we had this tool now that doubled progression-free and overall survival and made such a difference in this really horrible disease where patients do poorly. So, OS is technically immature here, but it's really trending very heavily towards improvement in overall survival. Importantly, the treatment-related adverse events in this, I mean, we know sacituzumab causes neutropenia, people who are experienced with this drug know how to manage it at this point. There wasn't any really unexpected treatment-related adverse events. You get some people with sacituzumab who have diarrhea. It's usually pretty manageable with some Imodium. So, it was cytopenias predominantly in this disease in this population that were highlighted as far as adverse events. But I'm going to be honest, like I was surprised that this wasn't the plenary over the SERENA-6 data because this, in my mind, there we have a practice-changing trial. I will immediately be trying to use this in my PD-L1 population because, to be honest, as a triple-negative breast cancer clinical specialist, when I get a patient with metastatic triple-negative breast cancer who's PD-L1 positive, I think, "Oh, thank God," because we know that part of the disease just does better in general. But now I have something that really could give them a durable response for much longer than I ever thought possible when I started really heavily treating this disease. And so, this was immediately practice-changing for me. Dr. Allison Zibelli: I think that it's pretty clear that this is at least an option, if not the option, for this group of patients. Dr. Rebecca Shatsky: Yeah, the duration of responses here was – it's just really important because, I mean, I do think this will make people live longer. Dr. Allison Zibelli: So, moving on to the final study that we're going to discuss today, neoCARHP (LBA500), which was neoadjuvant taxane plus trastuzumab, pertuzumab, plus or minus carbo(platin) in HER2-positive early breast cancer. I think this is a study a lot of us have been waiting for. What was the design and the results of this trial? Dr. Rebecca Shatsky: I was really excited about this as well because I'm one of those people that was waiting for this. This is a Chinese trial, so that is something to take note of. It wasn't an international trial, but it was a de-escalation trial which had become really popular in HER2-positive therapy because we know that we're overtreating HER2-positive breast cancer in a lot of patients. A lot of patients we're throwing the kitchen sink at it when maybe that is not necessary, and we can really de-escalate and try to personalize therapy a little bit better because these patients tend to do well. So, the standard of care, of course, in HER2-positive curative intent breast cancer with tumors that are greater than 2 cm is to give them the TCHP regimen, which is docetaxel, carboplatin, trastuzumab, and pertuzumab. And that was sort of established by several trials in the NeoSphere trial, and now it's been repeated in a lot of different studies as well. And so, that's really the standard of care that most people in the United States use for HER2-positive curative intent breast cancer. This was a trial to de-escalate the carboplatin, which I was super excited about because many of us who treat this disease a lot think carbo is the least important part of the therapy you're giving there. We don't really know that it's necessary. We've just been doing it for a long time, and we know that it adds a significant amount of toxicity. It causes thrombocytopenia, it causes severe nausea, really bad cytopenias that can be difficult in the last few cycles of this to manage. So, this trial was created. It randomized patients one to one with stage 2 and 3 HER2-positive breast cancer to either get THP, a taxane, pertuzumab, trastuzumab, similar to the what we do in first-line metastatic HER2-positive versus the whole TCHP with a carboplatin AUC of 6, which is what's pretty standard. And it was a non-inferiority trial, so important there. It wasn't to establish superiority of this regimen, which none of us, I think, were looking for it to. And it was a modified intent-to-treat population. And so, all patients got at least one cycle of this to be assessed as a standard for an intent-to-treat trial. And so, they assumed a pCR rate of about 62.8% for both groups. And, of course, it included both HER2-positive triple positives and ER negatives, which are, you know, a bit different diseases, to be honest, but we all kind of categorize them and treat them the same. And so, this trial was powered appropriately to detect a non-inferiority difference. And so, we had about 380 patients treated on both arms, and there was an absolute difference of only 1.8% of those treated with carbo versus those without. Which was fantastic because you really realized that de-escalation here may be something we can really do. And so, the patients who got, of course, the taxane regimen had fewer adverse events. They had way fewer grade 3 and 4 adverse events than the THP group. No treatment-associated deaths occur, which is pretty standard for- this is a pretty safe regimen, but it causes a lot of hospitalizations due to diarrhea, due to cytopenias, and neutropenic fever, of course. And so, I thought that this was something that I could potentially enact, you know, and be practice-changing. It's hard to say that when it's a trial that was only done in China, so it's not necessarily the United States population always. But I think for patients moving forward, especially those with, say, a 2.5 cm tumor, you know, node negative, those, I'd feel pretty comfortable not giving them the carboplatin here. Notes that I want to make about this population is that the majority were stage 2 and not stage 3. They weren't necessarily your inflammatory HER2-positive breast cancer patients. And that the taxane that was utilized in the trial is a little different than what we use in the United States. The patients were allowed to get nab-paclitaxel, which we don't have FDA approval for in the first-line curative intent setting for HER2-positive breast cancer in the United States. So, a lot of them got abraxane, and then they also got paclitaxel. We tend to use docetaxel every 3 weeks in the United States. So, just to point out that difference. We don't really know if that's important or not, but it's just a little bit different to the population we standardly treat. Dr. Allison Zibelli: So, are there patients that you would still give TCHP to? Dr. Rebecca Shatsky: Yeah, great question. I've been asked that a lot in the past like week since ASCO. I'd say in my inflammatory breast cancer patients, that's a group I do tend to sometimes throw the kitchen sink at. Now, I don't actually use AC in those because I know that that was the concern, but I think the TRAIN-2 trial really showed us you don't need to use Adriamycin in HER2-positive disease unless it's like refractory. So, I don't know that I would throw this on my stage 3C or inflammatory breast cancer patients yet because the majority of this were not stage 3. So, in your really highly lymph node positive patients, I'm a little bit hesitant to de-escalate them from the start. This is more of a like, if there's serious toxicity concerns, dropping carbo is absolutely fine here. Dr. Allison Zibelli: All right, great. Thank you, Dr. Shatsky, for sharing your valuable insights with us on the ASCO Daily News Podcast today. Dr. Rebecca Shatsky: Thanks so much, Dr. Zibelli and ASCO Daily News. I really want to thank you for inviting me to talk about this today. It was really fun, and I hope you find my opinions on some of this valuable. And so, I just want to thank everybody and my listeners as well. Dr. Allison Zibelli: And thank you to our listeners for joining us today. You'll find the links to all the abstracts discussed today in the transcript of this episode. Finally, if you like this podcast and you learn things from it, please take a moment to rate, review, and describe because it helps other people find us wherever you get your podcasts. Thank you again. Disclaimer: The purpose of this podcast is to educate and to inform. This is not a substitute for professional medical care and is not intended for use in the diagnosis or treatment of individual conditions. Guests on this podcast express their own opinions, experience, and conclusions. Guest statements on the podcast do not express the opinions of ASCO. The mention of any product, service, organization, activity, or therapy should not be construed as an ASCO endorsement. More on today's speakers Dr. Allison Zibelli Dr. Rebecca Shatsky @Dr_RShatsky Follow ASCO on social media: @ASCO on Twitter @ASCO on Bluesky ASCO on Facebook ASCO on LinkedIn Disclosures: Dr. Allison Zibelli: No relationships to disclose Dr. Rebecca Shatsky: Consulting or Advisory Role: Stemline, Astra Zeneca, Endeavor BioMedicines, Lilly, Novartis, TEMPUS, Guardant Health, Daiichi Sankyo/Astra Zeneca, Pfizer Research Funding (Inst.): OBI Pharma, Astra Zeneca, Greenwich LifeSciences, Briacell, Gilead, OnKure, QuantumLeap Health, Stemline Therapeutics, Regor Therapeutics, Greenwich LifeSciences, Alterome Therapeutics
This episode of Absolute Gene-ius slithers into the surprising science of invasive species monitoring with Dr. Brian Bahder. A childhood love of bugs led Brian to a dynamic career in entomology and plant pathology—and eventually to tracking large reptiles in the swamps of Florida.We dive deep into Brian's work developing multiplex digital PCR assays to detect DNA from snakes, caimans, and other invasive species using environmental samples like soil and water. He explains how this technology enables detection even after the animals are gone, and how sampling strategy, environmental variables, and experimental design are critical to getting reliable data. He also compares qPCR and digital PCR, emphasizing how each has its place depending on sensitivity, speed, and sample complexity.In the career corner, Brian shares how his academic journey was shaped by travel, risk-taking, and a healthy dose of failure. From surfing and skateboarding to discovering new species and running a diagnostic clinic, his path reminds us that science thrives on curiosity—and that even mistakenly detecting your own DNA can teach you something.Visit the Absolute Gene-ius pageto learn more about the guests, the hosts, and the Applied Biosystems QuantStudio Absolute Q Digital PCR System.
⚠️ This is a slideshow, so I strongly recommend watching the video episode.Jamie Andrews and his colleagues have shown that viruses probably don't exist, or if they do, they're not what we believe them to be..The Substack The Virology Controls Studies Project by Jamie Andrews challenges virology and genetic science. It aims to prove virology is flawed through simple control experiments.His team's control studies are simple experiments designed to test virology's claims by comparing samples that should show a virus with ones that shouldn't.For example, they use cell cultures with and without supposed viral material to see if they behave differently, like showing cell damage (cytopathic effects). They also run PCR tests on samples with no virus to check if they still give false positives.The conclusion is that virologists' methods are unreliable because the results often look the same whether a virus is present or not.
[01:02:32:15 - 01:03:00:26] — New COVID Variant “Nimbus” EmergesA new COVID-19 strain named NB.1.8.1 or "Nimbus" is spreading across Europe, the Americas, and the Pacific. Despite its presence, public reaction remains muted, and the WHO has struggled to reignite pandemic-level fear.[01:03:02:19 - 01:04:06:05] — COVID Death Stats & PCR Test ManipulationThe segment critiques how COVID deaths were reported, alleging that deaths from unrelated causes were labeled as COVID due to unreliable PCR tests. The fear was manufactured, not the illness itself.[01:06:50:17 - 01:07:40:08] — Nimbus Is Mild, But Messaging ContinuesDespite its spread, the WHO and CDC state that the Nimbus variant causes no more severe illness than previous strains. Symptoms are flu-like, but official guidance still pushes boosters and ongoing monitoring.[01:11:16:16 - 01:13:05:21] — RFK Jr. Challenges CNN on Vaccine TrialsRFK Jr. rebuts CNN's claims that childhood vaccines underwent placebo-controlled trials. He asserts that none used inert placebos and criticizes the CDC's licensing process for lacking true scientific rigor.[01:14:05:06 - 01:14:30:08] — Rise in Childhood Vaccines Since 1986Kennedy highlights that routine childhood shots have risen from 11 in 1986 to as many as 92 today. He argues this dramatic increase has occurred without sufficient safety testing, driven by profits over protection.[01:17:58:11 - 01:18:34:20] — CNN's Vaccine Trial Evidence DeconstructedRFK Jr. dissects CNN's list of 257 studies, explaining that the majority used active or post-licensure comparators, not inert placebos. He says the data actually supports his claims about inadequate safety trials.[01:28:18:00 - 01:28:42:14] — Vaccines, Chronic Illness, and AccountabilityHe argues that the explosion in autoimmune and chronic conditions among children should force a reevaluation of the vaccine schedule, especially products designed to alter the immune system without proper testing.[01:33:02:03 - 01:33:52:06] — Polio Cases Fell Before Vaccine RolloutData suggests polio mortality declined significantly before the vaccine was introduced. Kennedy and sources argue the impact of vaccines is overstated and that case definitions were changed to exaggerate success.[01:37:39:03 - 01:38:52:10] — Gardasil and the Dangers of Active PlacebosThe HPV vaccine Gardasil is cited as an example where placebo-controlled trials were misleading, as toxic aluminum adjuvants were used instead of inert substances. 90% of test subjects had adverse reactions.[01:47:08:10 - 01:48:07:20] — Clots in Children of Vaccinated MothersA disturbing case is reported of fibrous clots found in a 3-year-old born to a vaccinated mother. Additional studies suggest reduced IVF success and raise red flags about long-term generational health effects. [01:50:22:15 - 01:51:05:27] — Medical Gaslighting of Vaccine-Injured ChildrenA mother describes how her child became severely ill after vaccination, only to be dismissed by doctors who diagnosed her daughter with a psychological condition. Despite visible symptoms, she was offered antidepressants instead of real treatment.[01:51:49:14 - 01:52:18:05] — Parents Silenced, Doctors in DenialAcross the country, parents of vaccine-injured children say they are routinely ignored or belittled by medical professionals. RFK Jr. calls it a systematic campaign of gaslighting, protecting pharma over patients.[01:52:18:07 - 01:53:02:24] — CDC Profits from the Vaccines It PromotesRFK Jr. exposes the CDC's deep financial entanglement with the pharmaceutical industry—owning patents and earning royalties on vaccines—creating an undeniable conflict of interest.[01:54:07:21 - 01:54:54:02] — Government Pharma Pipeline: Vaccines for ProfitThe CDC, FDA, and NIH hold patents on dozens of vaccines and directly profit from licensing deals. These regulatory agencies now act as business partners to Big Pharma while maintaining a public image of oversight.[01:55:33:03 - 01:56:30:05] — The Hippocratic Oath Is DeadRFK Jr. accuses the medical establishment of abandoning its ethical foundation. He says doctors today are more concerned with protecting institutions than protecting patients, calling modern medicine morally bankrupt.[01:57:31:19 - 01:58:30:17] — Alarming Trends: Fertility Drops & Infant ClotsData from IVF clinics and anecdotal reports point to falling fertility and potential reproductive harms post-vaccination. A disturbing case involves a baby born with fibrous clots—raising fears of generational damage.[01:59:58:27 - 02:01:16:17] — Censorship That Kills: The Price of Silencing DissentRFK Jr. argues that medical censorship during COVID wasn't just wrong—it was deadly. Early treatments were discredited, expert voices silenced, and lives were lost in the name of “consensus.”[02:01:30:00 - 02:02:14:00] — Gold, Silver, and the Crumbling Dollar (Tony Arterburn)Tony Arterburn gives an update on the precious metals market, warning of long-term dollar instability. He explains how gold and silver remain reliable hedges against inflation and financial collapse, especially in times of political and institutional distrust03:13:23:17 – 03:14:07:04 — ICE Raids Expand NationwideTrump deploys ICE tactical units to five Democrat-controlled cities, including New York and Seattle, as Los Angeles goes into lockdown due to immigration riots. The move intensifies the administration's aggressive immigration crackdown.03:14:17:18 – 03:14:49:11 — Newsom Warns of Federal OverreachCalifornia Governor Gavin Newsom delivers an emotional speech warning that Trump's unilateral deployment of the National Guard could set a dangerous precedent, applying to every state and threatening democratic norms.03:27:43:17 – 03:28:42:22 — Mexican Official Talks Reclaiming U.S. LandA Mexican senator suggests reclaiming U.S. territory lost after the Treaty of Guadalupe Hidalgo, showing a historical map and implying that migration could serve as a tool to reassert Mexico's claim over the American Southwest.Follow the show on Kick and watch live every weekday 9:00am EST – 12:00pm EST https://kick.com/davidknightshow Money should have intrinsic value AND transactional privacy: Go to https://davidknight.gold/ for great deals on physical gold/silver For 10% off Gerald Celente's prescient Trends Journal, go to https://trendsjournal.com/ and enter the code KNIGHT Find out more about the show and where you can watch it at TheDavidKnightShow.comIf you would like to support the show and our family please consider subscribing monthly here: SubscribeStar https://www.subscribestar.com/the-david-knight-showOr you can send a donation throughMail: David Knight POB 994 Kodak, TN 37764Zelle: @DavidKnightShow@protonmail.comCash App at: $davidknightshowBTC to: bc1qkuec29hkuye4xse9unh7nptvu3y9qmv24vanh7Become a supporter of this podcast: https://www.spreaker.com/podcast/the-david-knight-show--2653468/support.
[01:02:32:15 - 01:03:00:26] — New COVID Variant “Nimbus” EmergesA new COVID-19 strain named NB.1.8.1 or "Nimbus" is spreading across Europe, the Americas, and the Pacific. Despite its presence, public reaction remains muted, and the WHO has struggled to reignite pandemic-level fear.[01:03:02:19 - 01:04:06:05] — COVID Death Stats & PCR Test ManipulationThe segment critiques how COVID deaths were reported, alleging that deaths from unrelated causes were labeled as COVID due to unreliable PCR tests. The fear was manufactured, not the illness itself.[01:06:50:17 - 01:07:40:08] — Nimbus Is Mild, But Messaging ContinuesDespite its spread, the WHO and CDC state that the Nimbus variant causes no more severe illness than previous strains. Symptoms are flu-like, but official guidance still pushes boosters and ongoing monitoring.[01:11:16:16 - 01:13:05:21] — RFK Jr. Challenges CNN on Vaccine TrialsRFK Jr. rebuts CNN's claims that childhood vaccines underwent placebo-controlled trials. He asserts that none used inert placebos and criticizes the CDC's licensing process for lacking true scientific rigor.[01:14:05:06 - 01:14:30:08] — Rise in Childhood Vaccines Since 1986Kennedy highlights that routine childhood shots have risen from 11 in 1986 to as many as 92 today. He argues this dramatic increase has occurred without sufficient safety testing, driven by profits over protection.[01:17:58:11 - 01:18:34:20] — CNN's Vaccine Trial Evidence DeconstructedRFK Jr. dissects CNN's list of 257 studies, explaining that the majority used active or post-licensure comparators, not inert placebos. He says the data actually supports his claims about inadequate safety trials.[01:28:18:00 - 01:28:42:14] — Vaccines, Chronic Illness, and AccountabilityHe argues that the explosion in autoimmune and chronic conditions among children should force a reevaluation of the vaccine schedule, especially products designed to alter the immune system without proper testing.[01:33:02:03 - 01:33:52:06] — Polio Cases Fell Before Vaccine RolloutData suggests polio mortality declined significantly before the vaccine was introduced. Kennedy and sources argue the impact of vaccines is overstated and that case definitions were changed to exaggerate success.[01:37:39:03 - 01:38:52:10] — Gardasil and the Dangers of Active PlacebosThe HPV vaccine Gardasil is cited as an example where placebo-controlled trials were misleading, as toxic aluminum adjuvants were used instead of inert substances. 90% of test subjects had adverse reactions.[01:47:08:10 - 01:48:07:20] — Clots in Children of Vaccinated MothersA disturbing case is reported of fibrous clots found in a 3-year-old born to a vaccinated mother. Additional studies suggest reduced IVF success and raise red flags about long-term generational health effects. [01:50:22:15 - 01:51:05:27] — Medical Gaslighting of Vaccine-Injured ChildrenA mother describes how her child became severely ill after vaccination, only to be dismissed by doctors who diagnosed her daughter with a psychological condition. Despite visible symptoms, she was offered antidepressants instead of real treatment.[01:51:49:14 - 01:52:18:05] — Parents Silenced, Doctors in DenialAcross the country, parents of vaccine-injured children say they are routinely ignored or belittled by medical professionals. RFK Jr. calls it a systematic campaign of gaslighting, protecting pharma over patients.[01:52:18:07 - 01:53:02:24] — CDC Profits from the Vaccines It PromotesRFK Jr. exposes the CDC's deep financial entanglement with the pharmaceutical industry—owning patents and earning royalties on vaccines—creating an undeniable conflict of interest.[01:54:07:21 - 01:54:54:02] — Government Pharma Pipeline: Vaccines for ProfitThe CDC, FDA, and NIH hold patents on dozens of vaccines and directly profit from licensing deals. These regulatory agencies now act as business partners to Big Pharma while maintaining a public image of oversight.[01:55:33:03 - 01:56:30:05] — The Hippocratic Oath Is DeadRFK Jr. accuses the medical establishment of abandoning its ethical foundation. He says doctors today are more concerned with protecting institutions than protecting patients, calling modern medicine morally bankrupt.[01:57:31:19 - 01:58:30:17] — Alarming Trends: Fertility Drops & Infant ClotsData from IVF clinics and anecdotal reports point to falling fertility and potential reproductive harms post-vaccination. A disturbing case involves a baby born with fibrous clots—raising fears of generational damage.[01:59:58:27 - 02:01:16:17] — Censorship That Kills: The Price of Silencing DissentRFK Jr. argues that medical censorship during COVID wasn't just wrong—it was deadly. Early treatments were discredited, expert voices silenced, and lives were lost in the name of “consensus.”[02:01:30:00 - 02:02:14:00] — Gold, Silver, and the Crumbling Dollar (Tony Arterburn)Tony Arterburn gives an update on the precious metals market, warning of long-term dollar instability. He explains how gold and silver remain reliable hedges against inflation and financial collapse, especially in times of political and institutional distrust03:13:23:17 – 03:14:07:04 — ICE Raids Expand NationwideTrump deploys ICE tactical units to five Democrat-controlled cities, including New York and Seattle, as Los Angeles goes into lockdown due to immigration riots. The move intensifies the administration's aggressive immigration crackdown.03:14:17:18 – 03:14:49:11 — Newsom Warns of Federal OverreachCalifornia Governor Gavin Newsom delivers an emotional speech warning that Trump's unilateral deployment of the National Guard could set a dangerous precedent, applying to every state and threatening democratic norms.03:27:43:17 – 03:28:42:22 — Mexican Official Talks Reclaiming U.S. LandA Mexican senator suggests reclaiming U.S. territory lost after the Treaty of Guadalupe Hidalgo, showing a historical map and implying that migration could serve as a tool to reassert Mexico's claim over the American Southwest.Follow the show on Kick and watch live every weekday 9:00am EST – 12:00pm EST https://kick.com/davidknightshow Money should have intrinsic value AND transactional privacy: Go to https://davidknight.gold/ for great deals on physical gold/silver For 10% off Gerald Celente's prescient Trends Journal, go to https://trendsjournal.com/ and enter the code KNIGHT Find out more about the show and where you can watch it at TheDavidKnightShow.comIf you would like to support the show and our family please consider subscribing monthly here: SubscribeStar https://www.subscribestar.com/the-david-knight-showOr you can send a donation throughMail: David Knight POB 994 Kodak, TN 37764Zelle: @DavidKnightShow@protonmail.comCash App at: $davidknightshowBTC to: bc1qkuec29hkuye4xse9unh7nptvu3y9qmv24vanh7Become a supporter of this podcast: https://www.spreaker.com/podcast/the-real-david-knight-show--5282736/support.
Send us a textScientific research at Yellowstone and other National Park has yielded many useful discoveries benefiting humanity. One of the most important was the discovery of the thermophilic bacterium, Thermus aquaticus. Later an enzyme was purified by a team led by Dr. Henry Erlich, which led to the practical use of the PCR test in covid detection and many other uses.Science in parks is a crucial tool for the advancement of humanity.However, if it were not for the early efforts of George Menendez Wright, science may have never taken hold in our national parks. Today, the George Wright Society continues that effort by supporting parks, protected/conserved areas, cultural sites, and other kinds of place-based conservation by encouraging communication among and convenings of researchers, managers, educators, practitioners, and the public to facilitate informed decisions and actions that embrace our values.Joining me to talk science in our national parks is Dave Harmon, executive director of the George Wright Society. Dave is responsible for overseeing the George Wright Society's operations, including co-editing Parks Stewardship Forum and helping plan workshops and other meetings. A member of the GWS since 1985, Dave began working for the organization in 1990 and served as executive director from 1998 to 2017 before returning that role in 2019. He is active in IUCN's World Commission on Protected Areas. He also maintains a research interest in the relationship between biological and cultural diversity, having co-founded the NGO Terralingua, which is devoted to that subject. Dave has co-edited several volumes on protected area conservation, including The Antiquities Act: A Century of American Archaeology, Historic Preservation, and Nature Conservation (with Francis P. McManamon and Dwight T. Pitcaithley), The Full Value of Parks: From Economics to the Intangible (with Allen D. Putney), and A Thinking Person's Guide to America's National Parks (with Robert Manning, Rolf Diamant, and Nora Mitchell).https:/natureandsciencepodcast.com
Hello and welcome to Entangled! The podcast where we explore the science of consciousness, the true nature of reality, and what it means to be a spiritual being having a human experience.I'm your host Jordan Youkilis, and today I'm joined by my friend Dr. Peter Petropulos, founder of Rejuvenate Wellness Center. In this episode, Dr. P details his career, from joining the Navy as a Medical Corpsman, moving into the medical school path, and ultimately focusing on traditional medicine, where he earned his Doctor of Chiropractic and started his own practice.Peter and I discuss the distinguishing characteristics of alternative / traditional medicine relative to western medicine, and how the Rockefellers changed the paradigm of modern medicine to focus on petrochemical, pharmaceutical based interventions. We then discuss problems associated with GMOs, pesticides, and forever chemicals, and the connections between Big Ag and Big Chemical.Next, we discuss the cost benefit analysis conducted by “leaders” of Big Pharma, and their callous decisions to roll out new medicines if their expected drug profits exceed expected litigation payouts. Dr. Petropulos explains why we need to make vaccine manufacturers liable again, after the disastrous decision in 1986 to pass the National Vaccine Childhood Injury Act.From there, we discuss the impact of DDT on paralytic disease, and the connection between the elimination of DDT and the reduction in polio. We consider vaccine orthodoxy, and why people are so afraid to question it, especially as it relates to autism.Dr. Petropulos explains why orthodoxy precludes us from looking for the real etiology of diseases and for real treatments. We ask why safe and efficacious treatments like ivermectin and hydroxychloroquine were suppressed during the pandemic, but deadly, dangerous interventions like remdesivir, molnupiravir, and ventilators were promoted.Next, we discuss the ruling elites' ties to Malthusian ideology, eugenics, and depopulation. Peter explains the process of virus isolation and genomic consensus, and why these are presumptive and speculative. We consider Dr. Fauci's long history of criminality, including during the AIDS epidemic, and the curious fact that Burroughs Wellcome manufactures both “poppers” and AZT.We then discuss the failures of PCR tests, and why its inventor, Dr. Kary Mullis, has been such a staunch opponent of Fauci for decades. We consider the correlation of flu epidemics and solar maximums, and the deregulating impact of electromagnetic frequency. We then discuss the fear propaganda pumped by the establishment, and the impact of weather manipulation on EMF stressors.From there, Dr. P explains how he has been involved with vaccine safety for decades, and how that connected him to Robert F. Kennedy, Jr. and Children's Health Defense. We consider how the media has been able to enforce vaccine orthodoxy. Dr. Petropulos explains his main hopes for Secretary Kennedy's HHS, including eliminating pharmaceutical advertising, removing indemnity from vaccine manufacturers, and ending the funding of medical schools by criminal NGOs.We then discuss the need for COVID-19 pandemic accountability, and our hopes that Attorney General Pam Bondi will bring justice to the biggest perpetrators of the Plandemic fraud, including Tony Fauci, George Soros and Bill Gates. We then consider the revolution of media and the high caliber of content being produced today. Dr. Petropulos explains how he came around to the MAGA MAHA Alliance, and why President Trump needs to take ownership for the failures of Operation Warp Speed.We then discuss the release of the Epstein files and his connections to intelligence, organized crime, and the elitist class. We consider the use of sexual blackmail as a tool of control and its insidious ties to the occult. We ask what the future has in store for the oligarchy, and discuss why the central bankers need to be held accountable for their crimes against humanity.Peter and I then discuss political reform at the state and local level, the future of the Democratic party, and how to end the polarization of politics. Dr. P describes the expansion of Children's Health Defense to Colorado, the spread of information related to vaccine injuries, and the increase in sudden deaths following the COVID “vaccination” program.Dr. P describes the importance of shifting off a mandatory vaccine schedule and the ethical necessity of informed consent. We conclude the conversation highlighting COVID-19 as a moment of awakening for the general public and for influential members of the scientific community.This outro is titled: “Vaxxed & Unafraid”. Music from the show is available on the Spotify playlist “Entangled – The Vibes”. If you like the show, please drop a 5-star review and subscribe on Substack, Spotify, X, Apple or wherever you listen to podcasts.Please enjoy the episode!Music: Intro: Ben Fox - "The Vibe". End Credits: Maya Pacziga – “Healing”.Outro: “Vaxxed & Unafraid” starts at 1:30:00.Recorded: 02/14/25. Published: 06/03/25.Check out the resources mentioned:* Rejuvenate Wellness Center: https://www.rejuvenatewellnesscenter.com/* The AIDS War: Propaganda, Profiteering, and Genocide from the Medical Industrial Complex by John Lauritsen: https://a.co/d/fEJLqKm* A Farewell to Virology by Dr. Mark Bailey: https://a.co/d/flpVbTr* Virus Mania: How the Medical Industry Continually Invents Epidemics, Making Billion-Dollar Profits At Our Expense by Torsten Engelbrecht and Claus Kohnlein: https://a.co/d/cf52SOG* The Truth About Contagion: Exploring Theories of How Disease Spreads by Dr. Thomas Cowan and Saly Fallon Morell: https://a.co/d/bi37Phj* Inventing the AIDS Virus by Peter Duesberg: https://a.co/d/8hPUgCh This is a public episode. If you would like to discuss this with other subscribers or get access to bonus episodes, visit entangledpodcast.substack.com
00:02:32 - 00:06:30: Critique of Trump's “Big Beautiful Bill” - Analyzes Trump's bill, which increases national debt by $3.3 trillion, includes tax cuts like no taxes on tips, but prioritizes military spending over real cuts. Highlights Ron Paul's call to reduce military-industrial complex expenditure. 00:26:15 - 00:31:52: Central Bank Digital Currencies (CBDCs) and Control - Discusses globalist agenda for CBDCs, quoting Augustine Carstens on centralized control and transaction tracking, warning of threats to personal freedom and privacy. 01:02:12 - 01:09:32: AI Manipulation on Social Media - Covers University of Zurich experiment where AI bots on Reddit manipulated users' beliefs through lies and targeted vulnerabilities, raising ethical concerns about AI-driven propaganda. 01:16:52 - 01:17:33: Show Introduction and Music Appreciation - Welcomes listeners back to the David Knight Show, acknowledges a viewer's comment praising David's music for breaks, and mentions a potential relaxed evening stream. 01:18:26 - 01:25:12: Pastor on Angels and Demons - Pastor Alan Jackson discusses his book Angels, Demons and You, emphasizing the reality of spiritual forces, their role in the gospel, and the church's disconnect from these truths due to rationalism and a diluted gospel. 01:25:42 - 01:35:35: Pagan Indoctrination in Schools - Reports on Chicago schools forcing Hindu rituals on students via the David Lynch Foundation, leading to a $2.6M settlement. Highlights broader pagan indoctrination (Hinduism, Buddhism, Islam) in U.S. public schools, rooted in anti-Christian agendas. 01:44:40 - 01:51:48: COVID Death Misinformation - Critiques ABC News' claim of 300+ weekly U.S. COVID deaths, alleging manipulated data (PCR tests, misattributed causes) and fearmongering to push vaccines, despite low uptake and known risks. 01:51:48 - 01:58:44: Vaccine Harms and Misreporting - Discusses adverse effects of COVID vaccines (e.g., renal failure), underreporting in VAERS, and the dangers of live virus vaccines, supported by audience comments from a paramedic and others. Follow the show on Kick and watch live every weekday 9:00am EST – 12:00pm EST https://kick.com/davidknightshow Money should have intrinsic value AND transactional privacy: Go to https://davidknight.gold/ for great deals on physical gold/silver For 10% off Gerald Celente's prescient Trends Journal, go to https://trendsjournal.com/ and enter the code KNIGHT Find out more about the show and where you can watch it at TheDavidKnightShow.comIf you would like to support the show and our family please consider subscribing monthly here: SubscribeStar https://www.subscribestar.com/the-david-knight-showOr you can send a donation throughMail: David Knight POB 994 Kodak, TN 37764Zelle: @DavidKnightShow@protonmail.comCash App at: $davidknightshowBTC to: bc1qkuec29hkuye4xse9unh7nptvu3y9qmv24vanh7Become a supporter of this podcast: https://www.spreaker.com/podcast/the-david-knight-show--2653468/support.
00:02:32 - 00:06:30: Critique of Trump's “Big Beautiful Bill” - Analyzes Trump's bill, which increases national debt by $3.3 trillion, includes tax cuts like no taxes on tips, but prioritizes military spending over real cuts. Highlights Ron Paul's call to reduce military-industrial complex expenditure. 00:26:15 - 00:31:52: Central Bank Digital Currencies (CBDCs) and Control - Discusses globalist agenda for CBDCs, quoting Augustine Carstens on centralized control and transaction tracking, warning of threats to personal freedom and privacy. 01:02:12 - 01:09:32: AI Manipulation on Social Media - Covers University of Zurich experiment where AI bots on Reddit manipulated users' beliefs through lies and targeted vulnerabilities, raising ethical concerns about AI-driven propaganda. 01:16:52 - 01:17:33: Show Introduction and Music Appreciation - Welcomes listeners back to the David Knight Show, acknowledges a viewer's comment praising David's music for breaks, and mentions a potential relaxed evening stream. 01:18:26 - 01:25:12: Pastor on Angels and Demons - Pastor Alan Jackson discusses his book Angels, Demons and You, emphasizing the reality of spiritual forces, their role in the gospel, and the church's disconnect from these truths due to rationalism and a diluted gospel. 01:25:42 - 01:35:35: Pagan Indoctrination in Schools - Reports on Chicago schools forcing Hindu rituals on students via the David Lynch Foundation, leading to a $2.6M settlement. Highlights broader pagan indoctrination (Hinduism, Buddhism, Islam) in U.S. public schools, rooted in anti-Christian agendas. 01:44:40 - 01:51:48: COVID Death Misinformation - Critiques ABC News' claim of 300+ weekly U.S. COVID deaths, alleging manipulated data (PCR tests, misattributed causes) and fearmongering to push vaccines, despite low uptake and known risks. 01:51:48 - 01:58:44: Vaccine Harms and Misreporting - Discusses adverse effects of COVID vaccines (e.g., renal failure), underreporting in VAERS, and the dangers of live virus vaccines, supported by audience comments from a paramedic and others. Follow the show on Kick and watch live every weekday 9:00am EST – 12:00pm EST https://kick.com/davidknightshow Money should have intrinsic value AND transactional privacy: Go to https://davidknight.gold/ for great deals on physical gold/silver For 10% off Gerald Celente's prescient Trends Journal, go to https://trendsjournal.com/ and enter the code KNIGHT Find out more about the show and where you can watch it at TheDavidKnightShow.comIf you would like to support the show and our family please consider subscribing monthly here: SubscribeStar https://www.subscribestar.com/the-david-knight-showOr you can send a donation throughMail: David Knight POB 994 Kodak, TN 37764Zelle: @DavidKnightShow@protonmail.comCash App at: $davidknightshowBTC to: bc1qkuec29hkuye4xse9unh7nptvu3y9qmv24vanh7Become a supporter of this podcast: https://www.spreaker.com/podcast/the-real-david-knight-show--5282736/support.
Fresh off Spring Break DJ Boss Player and the Mori Show came to give you the special podcast flavor you love. Peep it!
DJ Boss Player and the Mori Show aka Sugar Plug are just poddin' giving y'all vibez from the stratosphere!
Boss Playa from the Himalayas and The Mori Show kick it for your listening pleasure!
What's good? DJ Boss Player and the Mori Show aka Sugar Plug were coolin on the set waxing philosophical. Pull up a chair, have a seat and join us!
The revolution will not be televised, but's live on your radio right now! Shoutout to the Pop Culture Revolutionaries! Check out this week's vibez with DJ Boss Player and The Mori Show!
DJ Boss Player and The Mori Show aka Sugar Plug were waxing nostalgic for their last show at WMUC! Shoutout to all the former Hip-Hop Corner show and Pop Culture Revolution cohosts! We're on to bigger and better things! Stay tuned!
Dr. John Sweetenham and Dr. Erika Hamilton discuss top abstracts that will be presented at the 2025 ASCO Annual Meeting, including research on tech innovations that could shape the future of oncology. Transcript Dr. John Sweetenham: Hello, and welcome to the ASCO Daily News Podcast. I'm your host, Dr. John Sweetenham, and I'm delighted to be joined today by Dr. Erika Hamilton, a medical oncologist and director of breast cancer and gynecologic cancer research at the Sarah Cannon Research Institute in Nashville, Tennessee. Dr. Hamilton is also the chair of the 2025 ASCO Annual Meeting Scientific Program, and she's here to tell us about some of the key abstracts, hot topics, and novel approaches in cancer care that will be featured at this year's Annual Meeting. Our full disclosures are available in the transcript of this episode. Dr. Hamilton, it's great to have you on the podcast today, and thanks so much for being here. Dr. Erika Hamilton: Thanks, Dr. Sweetenham. I'm glad to be here. Dr. John Sweetenham: Dr. Hamilton, the Presidential Theme of the Annual Meeting this year is ‘Driving Knowledge to Action: Building a Better Future,' and that's reflected in many of the sessions that will focus on action-oriented guidance to improve care for our patients. And as always, there'll be great presentations on practice-changing abstracts that will change treatment paradigms and transform care. Can you tell us about some of the hot topics this year and what you're particularly excited about? Dr. Erika Hamilton: You're right. Dr. Robin Zon's theme is ‘Driving Knowledge to Action: Building a Better Future,' and you're going to see that theme really interlaced throughout the ASCO program this year. We had a record number of submissions. Over 5,000 abstracts will be published, and there'll be about 3,000 presentations, either in oral format or poster presentations. We have 200 dynamic sessions. Many of the discussants will be highlighting key takeaways and how we can translate action-oriented guidance to better treat our patients to build a better future. Our state-of-the-art science will include a Plenary Session. This will feature presentations as well as discussion of each of the presentations for clinical late-breaking abstracts. We have Clinical Science Symposia that I'm particularly excited about this year. These will feature key abstracts as well as discussions and a foundational talk around the subject. We're covering novel antibody-drug conjugate targets, turning “cold” tumors “hot” to include CAR T, as well as the future of cancer detection. There'll be rapid oral abstracts, case-based panels, and this will also feature interactive audience polling and case discussions. I also want to highlight the community connection opportunities. There will be 13 Communities of Practice that will be meeting on-site during ASCO, and there's also really a plethora of networking opportunities for trainees and early-career professionals, a Women's Networking Center, a patient advocate space, and I'm happy to report there will also be live music out on the terrace this year at ASCO. Dr. John Sweetenham: Well, that's going to be a really great addition. I have to say, I think this is always a special time of year because excitement starts to mount as the meeting gets closer and closer. And once the abstracts are out there, I certainly personally feel that the excitement builds. Talking of abstracts, let's dive into some of the key abstracts for this year's meeting. I'd like to start out by asking you about Abstract 505. This reports on 15-year outcomes for women with premenopausal hormone receptor-positive early breast cancer in the SOFT and TEXT trials. It assesses the benefits of adjuvant exemestane and ovarian function suppression or tamoxifen and ovarian function suppression. So, could you talk us through this and tell us what you think the key takeaways from this abstract are? Dr. Erika Hamilton: Absolutely. This is essentially the SOFT and TEXT trials. They are trials that we've been following for quite some time, evidenced by the 15-year outcome. And I think it really answers two very important questions for us regarding adjuvant endocrine therapy for patients that are facing hormone receptor-positive disease. The benefit of ovarian function suppression for one, and then second, the benefit of exemestane over tamoxifen, which is our SERM [selective estrogen receptor modulator]. So, in terms of the SOFT trial, when we talk about distance recurrence-free interval, which I really think is probably the most meaningful because secondary cancers, et cetera, are not really what we're getting at here. But in terms of distant recurrence-free interval, certainly with tamoxifen, using tamoxifen plus ovarian function suppression adds a little bit. But where we really get additional benefits are by moving to exemestane, an aromatase inhibitor with the ovarian function suppression. So, for example, in SOFT, for distant recurrence-free interval for patients that have received prior chemotherapy, the distance recurrence-free interval was 73.5% with tamoxifen, bumped up just a tiny bit to 73.8% with ovarian function suppression. But when we used both ovarian function suppression and switched to that aromatase inhibitor, we're now talking about 77.6%. It may seem like these are small numbers, but when we talk about an absolute benefit of 4%, these are the type of decisions that we decide whether to offer chemotherapy based on. So, really just optimizing endocrine therapy really can provide additional benefits for these patients. Just briefly, when we turn to TEXT, similarly, when we look at distance recurrence-free interval for our patients that are at highest risk and receive chemotherapy, tamoxifen and ovarian function suppression, 79%; 81% with exemestane and ovarian function suppression. And when we talk about our patients that did not receive chemotherapy, it increased from 91.6% up to 94.6%—very similar that 3% to 4% number. So, I think that this is just very important information when counseling our patients about the decisions that they're going to make for themselves in the adjuvant setting and how much we want to optimize endocrine therapy. Dr. John Sweetenham: Thanks so much for your insight into that. Dr. Erika Hamilton: Yeah, absolutely. So, let's turn to hematologic malignancies. Abstract 6506 reports exciting results on the new agent ziftomenib in relapsed/refractory NPM1-mutant acute myeloid leukemia. This is a phase 1b clinical activity study and safety results. This was the pivotal KOMET-001 study. And my question is, will this new agent fulfill an unmet need in this NPM1 space? Dr. John Sweetenham: Yeah, great question. And I think the answer is almost certainly ‘yes'. So, just as some brief background, NPM1 mutation is known to be a driver of leukemogenesis in around 30% of patients with AML, and it's a poor prognostic factor. And typically, about 50% of these patients will relapse within a year of their first-line therapy, and only around 10% of them will get a subsequent complete remission with salvage therapy. Menin inhibitors, which disrupt the interaction between menin and KMT2A, are known to be active in NPM1-mutated as well as in KMT2A-rearranged AML. And ziftomenib is a selective oral menin inhibitor, which in this study was evaluated at a dose of 600 mg once a day, as you mentioned, a phase 1b/2 study, which is multicenter and presented by Dr. Eunice Wang from Roswell Park. It's a relatively large study of 112 patients who were treated with this standard dose with relatively short median follow-up at this time. The median age was 69 years, and median prior therapies were two, but with a range of one to seven. And I think very importantly, 60% of these patients had previously been treated with venetoclax, and 23% of them had had a prior transplant. Looking at the results overall for this study, the overall response rate was 35%, which is actually quite impressive. Specifically for those patients in the phase 2 part of the study, around 23% achieved a CR [complete remission] or CRh [complete remission with partial hematologic recovery]. What's very interesting in my mind is that the response rates were comparable in venetoclax-naive and venetoclax-exposed patients. And the drug was very well tolerated, with only 3% of patients having to discontinue because of treatment-related adverse events. And I think the authors appropriately conclude that, first of all, the phase 2 primary endpoint in the study was met, and that ziftomenib achieved deep and durable responses in relapsed and refractory NPM1-mutated AML, regardless of prior venetoclax, with good tolerance of the drug. And so, I think putting all of this together, undoubtedly, these data do support the potential use of this agent as monotherapy and as a new option for those patients who have relapsed or refractory NPM1-mutated acute myeloid leukemia. So, let's move on a little bit more now and change the subject and change gears completely and talk about circulating tumor DNA [ctDNA]. This has been a hot topic over a number of years now, and at this year's meeting, there are quite a few impactful studies on the use of ctDNA. We have time to focus on just one of these, and I wanted to get your thoughts on Abstract 4503. This is from the NIAGARA trial, which looks at ctDNA in patients with muscle-invasive bladder cancer who receive perioperative durvalumab. Could you tell us a little bit about this study? Dr. Erika Hamilton: So, this was the phase 3 NIAGARA trial, and this is literally looking for patients with muscle-invasive bladder cancer that are cisplatin-eligible, and the addition of durvalumab to neoadjuvant chemotherapy. So here, this is a planned exploratory analysis of ctDNA and the association with clinical outcomes from NIAGARA. So, this is really the type of study that helps us determine which of our patients are more likely to have a good outcome and which of our patients are more likely not to. There were 1,000 randomized patients in this study, and 462 comprised the biomarker-evaluable population. There were about half in the control arm and half in the durvalumab arm. And overall, the ctDNA-positive rate at baseline was about 57%, or a little over half, and that had decreased to about 22% after neoadjuvant treatment. ctDNA clearance rates from baseline to pre-radical cystectomy was about 41% among those with durvalumab and 31% among those in control. And the non-pCR rate was 97% among patients with pre-cystectomy ctDNA-positive status. So, this really gives us some information about predicting who is going to have better outcomes here. We did see a disease-free survival benefit with perioperative durvalumab, and this was observed in post-cystectomy ctDNA-positive as well as the ctDNA-negative groups. Shifting gears now to GI cancer, Abstract 3506 is a long-term safety and efficacy study of sotorasib plus panitumumab and FOLFIRI for previously treated KRAS G12C-mutated metastatic colorectal cancer. And this is the CodeBreaK-101 study. What are your thoughts on this study? Dr. John Sweetenham: Yeah, thanks. A very interesting study, and this abstract builds upon the phase 3 CodeBreaK-300 trial, which I think has just been published in the Journal of Clinical Oncology. This showed that the combination of sotorasib and panitumumab improved clinical outcomes in patients with chemorefractory KRAS G12C-mutated metastatic colorectal cancer. The current abstract, as you mentioned, reports the CodeBreaK-101 trial. And this was a phase 1b trial where FOLFIRI therapy was added to sotorasib and panitumumab in previously treated patients with KRAS G12C-mutated metastatic colorectal cancer. The abstract reports the overall and progression-free survival results, as well as some updated safety and response data. So, in this study, patients with this particular mutation who had received at least one prior systemic treatment but were KRAS G12C inhibitor-naive were enrolled into an expansion cohort of the CodeBreaK-101 protocol. And these patients received what apparently now recommended as the standard phase 2 dose of sotorasib of 960 mg daily, plus panitumumab and a standard dose of FOLFIRI. And the primary endpoint of the study was safety, and secondary endpoints included confirmed response, overall response, and progression-free survival, as assessed by the investigator. And by November of last year, 40 patients had been enrolled into this study. Common treatment-related adverse events were cutaneous; some patients developed neutropenia, and stomatitis was fairly widespread. Discontinuation of sotorasib because of adverse events was only seen in 1% of patients, although patients did have to discontinue because of toxicity from some of the other agents in the combination. Looking at the results of this study, the updated objective response rate was 57.5%, and the disease control rate was estimated at 92%, going on 93%, with a median time to response of 1.6 months and a median response duration of 6 months. After a median follow-up of 29.2 months, the median progression-free survival was 8.2 months, and the overall survival 17.9 months. So, the authors have concluded that this combination, including sotorasib, panitumumab, and FOLFIRI, does appear to show quite promising long-term efficacy in pretreated patients with this specific mutation. The ongoing phase 3 study they mentioned, CodeBreaK-301, is aiming to evaluate this combination against the standard of care in the first-line setting for patients with KRAS G12C-mutated colorectal cancer. So, promising results, and we'd be very interested to see how this particular combination performs in the frontline. Dr. Erika Hamilton: Fantastic. Thanks so much for sharing that. Let's shift gears again and really talk about digital technology. I feel that we're all going to have to get much better with this, and really, there are a lot of promises for our patients coming here. There are a lot of abstracts at ASCO that are focusing on innovations in digital technology, including a really interesting psychosocial digital application for caregivers of patients that are undergoing hematopoietic stem cell transplantation. Can you tell us a little bit about this? It's Abstract 11000. Dr. John Sweetenham: Yeah, absolutely. This abstract certainly caught my eye, and I think it's intriguing for a number of reasons, partly because it's app-based, and partly also because it specifically addresses caregiver burden and caregiver needs in the oncology setting, which I think is especially important. And although the context, the clinical context of this study, is hematopoietic stem cell transplantation, I think it has potential applications way beyond that. We all know that caregivers of patients undergoing stem cell transplantation have significant quality-of-life struggles. They are well-documented to have significant psychological and emotional strain before, during, and after stem cell transplantation. And this abstract describes an application called BMT-CARE, which is aimed at improving caregivers' quality of life, caregiver burden, mood symptoms, and coping skills, and so on. So, this was a single-center, randomized trial from MGH [Massachusetts General Hospital] of this app for stem cell transplant caregivers, compared with usual care in those individuals. And the eligible patients, or eligible individuals, were adults caring for patients with heme malignancy undergoing either an autologous or an allogeneic stem cell transplant. Patients were randomly assigned either to use the app or for usual care. And the app itself—and I think it'll be interesting to actually see this at the meeting and visualize it and see how user-friendly and so on it is—but it comprises five modules, which integrate psychoeducation, behavior change, stress management, and they're delivered through a kind of interactive platform of educational games and videos. And then participants were self-reporting at baseline and then 60 days after transplant. So, around 125 patients were enrolled in this study, of around 174 who were initially approached. So, just over 70% uptake from caregivers, which is, I think, relatively high, and evenly distributed between the two randomized arms. And the majority of the participants were spouses. And at 60 days post-stem cell transplant, the intervention participants reported a better quality of life compared with those who received usual care. If you break this down a little bit more, these participants reported lower caregiving burden, lower incidence of depression, fewer PTSD symptoms, and overall better coping skills. So, the authors conclude that this particular app, a digital health intervention, led to pretty substantial improvements in quality of life for these caregivers. So, intriguing. As I said, it'll be particularly interesting to see how this thing looks during the meeting. But if these kind of results can be reproduced, I think this sort of application has potential uses way beyond the stem cell transplant setting. Dr. Erika Hamilton: Yeah, I find that just so fascinating and very needed. I think that the caregiving role is often underestimated in how important that is for the patient and the whole family, and really giving our caregivers more tools in their toolbox certainly is quite helpful. Dr. John Sweetenham: Absolutely. Well, the meeting is getting closer, and as I mentioned earlier, I think anticipation is mounting. And I wanted to say thanks so much to you for chatting with me today about some of the interesting advances in oncology that we're going to see at this year's meeting. There is a great deal more to come. Our listeners can access links to the studies we've discussed today in the transcript of this episode. I'm also looking forward, Dr. Hamilton, to having you back on the podcast after the Annual Meeting to dive into some of the late-breaking abstracts and some of the other key science that's captured the headlines this year. So, thanks once again for joining me today. Dr. Erika Hamilton: Thanks so much for having me. Pleasure. Dr. John Sweetenham: And thank you to our listeners for joining us today. Be sure to catch my “Top Takeaways from ASCO25.” These are short episodes that will drop each day of the meeting at 5:30 p.m. Eastern Time. So, subscribe to the ASCO Daily News Podcast wherever you prefer to listen, and join me for concise analyses of the meeting's key abstracts. Disclaimer: The purpose of this podcast is to educate and to inform. This is not a substitute for professional medical care and is not intended for use in the diagnosis or treatment of individual conditions. Guests on this podcast express their own opinions, experience, and conclusions. Guest statements on the podcast do not express the opinions of ASCO. The mention of any product, service, organization, activity, or therapy should not be construed as an ASCO endorsement. More on today's speakers: Dr. John Sweetenham Dr. Erika Hamilton @erikahamilton9 Follow ASCO on social media: @ASCO on Twitter ASCO on Bluesky ASCO on Facebook ASCO on LinkedIn Disclosures: Dr. John Sweetenham: No relationships to disclose Dr. Erika Hamilton: Consulting or Advisory Role (Inst): Pfizer, Genentech/Roche, Lilly, Daiichi Sankyo, Mersana, AstraZeneca, Novartis, Ellipses Pharma, Olema Pharmaceuticals, Stemline Therapeutics, Tubulis, Verascity Science, Theratechnologies, Accutar Biotechnology, Entos, Fosun Pharma, Gilead Sciences, Jazz Pharmaceuticals, Medical Pharma Services, Hosun Pharma, Zentalis Pharmaceuticals, Jefferies, Tempus Labs, Arvinas, Circle Pharma, Janssen, Johnson and Johnson Research Funding (Inst): AstraZeneca, Hutchison MediPharma, OncoMed, MedImmune, Stem CentRx, Genentech/Roche, Curis, Verastem, Zymeworks, Syndax, Lycera, Rgenix, Novartis, Millenium, TapImmune, Inc., Lilly, Pfizer, Lilly, Pfizer, Tesaro, Boehringer Ingelheim, H3 Biomedicine, Radius Health, Acerta Pharma, Macrogenics, Abbvie, Immunomedics, Fujifilm, eFFECTOR Therapeutics, Merus, Nucana, Regeneron, Leap Therapeutics, Taiho Pharmaceuticals, EMD Serono, Daiichi Sankyo, ArQule, Syros Pharmaceuticals, Clovis Oncology, CytomX Therapeutics, InventisBio, Deciphera, Sermonix Pharmaceuticals, Zenith Epigentics, Arvinas, Harpoon, Black Diamond, Orinove, Molecular Templates, Seattle Genetics, Compugen, GI Therapeutics, Karyopharm Therapeutics, Dana-Farber Cancer Hospital, Shattuck Labs, PharmaMar, Olema Pharmaceuticals, Immunogen, Plexxikon, Amgen, Akesobio Australia, ADC Therapeutics, AtlasMedx, Aravive, Ellipses Pharma, Incyte, MabSpace Biosciences, ORIC Pharmaceuticals, Pieris Pharmaceuticals, Pieris Pharmaceuticals, Pionyr, Repetoire Immune Medicines, Treadwell Therapeutics, Accutar Biotech, Artios, Bliss Biopharmaceutical, Cascadian Therapeutics, Dantari, Duality Biologics, Elucida Oncology, Infinity Pharmaceuticals, Relay Therapeutics, Tolmar, Torque, BeiGene, Context Therapeutics, K-Group Beta, Kind Pharmaceuticals, Loxo Oncology, Oncothyreon, Orum Therapeutics, Prelude Therapeutics, Profound Bio, Cullinan Oncology, Bristol-Myers Squib, Eisai, Fochon Pharmaceuticals, Gilead Sciences, Inspirna, Myriad Genetics, Silverback Therapeutics, Stemline Therapeutics
Ever thought about why medications work differently for different people? In this episode of Absolute Gene-ius, we explore the exciting field of pharmacogenomics with Wendy Wang, pharmacogenetic laboratory supervisor at Children's Mercy Hospital in Kansas City. Wendy shares how genetics can influence drug metabolism, offering a glimpse into how precision medicine can revolutionize healthcare by tailoring treatments based on an individual's unique genetic makeup.At the heart of Wendy's research is CYP2D6, a cytochrome P450 enzyme responsible for metabolizing around 20% of all prescribed medications. She explains how her lab uses digital PCR to analyze copy number variations (CNV), offering a reliable and precise method to predict drug metabolism. Wendy dives into the complexities of structural variants, the role of digital PCR in enhancing assay efficiency, and why pharmacogenomics is a critical piece of the precision medicine puzzle. Her use of delightful metaphors—like comparing genetic testing to ladling soup—makes complex science both relatable and engaging.In the Career Corner, Wendy opens up about her winding path to molecular biology, which included studying classical antiquity and nearly pursuing a career in history. She emphasizes the importance of resilience in research, embracing failure as a learning opportunity, and encourages budding scientists to reach out to mentors and explore diverse interests. Plus, hear about her most embarrassing lab mishap (hint: it involves a fire alarm) and the proud moment of publishing her first, first-author paper.Visit the Absolute Gene-ius page to learn more about the guests, the hosts, and the Applied Biosystems QuantStudio Absolute Q Digital PCR System.
IVF Clinic Bombing and Pro-Mortalism Ideology (00:02:09 - 00:09:27)Guy Edward Bartkus bombed a Palm Springs IVF clinic, killing himself and injuring five, motivated by pro-mortalism (life causes suffering, death is liberation). His manifesto, hosted on promortalism.com, rails against pro-lifers and life itself, reflecting a nihilistic, anti-human philosophy rooted in online subcultures.Cultural Nihilism and Social Media's Role (00:13:03 - 00:24:28)The bomber's pro-mortalism reflects a broader cultural nihilism, influenced by ideas like Gaia theory (humans as a virus) and amplified by social media platforms. Reddit, TikTok, and Tumblr are criticized as hubs for pseudo-intellectualism, fostering anti-life ideologies among isolated individuals.Bible Engagement as a Positive Trend (00:24:28 - 00:31:02)A LifeWay survey shows 48% of Americans view the Bible as true (up from 36% in 2016), with rising Bible sales and reading. This suggests a growing rejection of secular humanism and a return to spiritual values amid cultural nihilism.Covid as a Scam (Music Man Analogy) (00:41:36 - 00:50:18)A Brownstone Institute article compares the Covid response to The Music Man, where fear (inflated death counts, PCR test misuse) enriched “snake oil salesmen” like Fauci. This mirrors historical fearmongering (9/11, Waco) to erode rights, with elites profiting from compliance.Trump's Tariffs Impact on Small Businesses (01:11:21 - 01:16:20)An NFIB survey shows Trump's unpredictable tariffs are reducing small business optimism (down to 95.8, below the 51-year average), creating market uncertainty akin to Covid-era disruption. Small businesses face tight margins, reduced hiring, and stalled investments, with tech sector impacts highlighted by YouTubers Louis Rossman and Gamers Nexus.DEA Corruption in Drug War (01:27:30 - 01:35:58)An AP article reveals Diego Marin, a Cali cartel figure, evaded capture with DEA complicity, bribing agents while building a $100M money-laundering empire. Compared to Whitey Bulger and Iran-Contra, it's framed as a problem-reaction-solution tactic to expand the police state.Mexican Navy Ship Crash (01:37:07 - 01:39:26)An NBC News report describes a Mexican Navy sailing ship crashing into the Brooklyn Bridge, killing two and injuring 22 due to a mechanical failure. The surreal event stunned New Yorkers, highlighting the unexpected nature of Mexico's sailing navy.CDC Covid Vaccine Recommendations (01:52:26 - 01:56:33)A Wall Street Journal article reports the Trump administration plans to drop routine Covid vaccine recommendations for pregnant women, teenagers, and children, led by HHS Secretary RFK Jr. The host criticizes the CDC's blanket recommendation (everyone 6 months and older) due to no long-term safety data, profit-driven motives, and harmful side effects, arguing the vaccine should be removed entirely.HHS Covid Vaccine Recommendations and Authority (02:05:33 - 02:13:16)Dr. Ruby critiques HHS's plan to stop recommending Covid vaccines for children and pregnant women as a red herring, given its authority over FDA, NIH, CMS, and CDC to demand immediate removal. She warns of deceptive terms like “considering” and questions state chemtrail bans, citing federal exemptions (Title 50, Prep Act) and global air circulation, suspecting controlled opposition.Novavax Approval Critique and Bird Flu (02:21:20 - 02:30:03)The FDA fully approved Novavax's Covid shot, marketed as non-mRNA but using synthetic spike proteins from moth cells, posing risks like myocarditis with no long-term studies. Dr. Ruby warns of off-label use and compares it to Pfizer/Moderna's rollout. She critiques bird flu as a fabricated threat, with chicken culling inflating egg prices and testing economic control, not addressing real disease.Vaccine Shedding and Industry Protections (02:16:43 - 02:51:36)Pfizer's investigator brochure admits Covid vaccine shedding via inhalation and skin contact, raising concerns about unknown contents affecting unvaccinated individuals. Dr. Ruby highlights the vaccine industry's Prep Act immunity, with government payouts in vaccine court, and Pfizer's 50% non-disclosure agreement, allowing undisclosed ingredients, akin to coercive contracts demanding country assets.Follow the show on Kick and watch live every weekday 9:00am EST – 12:00pm EST https://kick.com/davidknightshow Money should have intrinsic value AND transactional privacy: Go to https://davidknight.gold/ for great deals on physical gold/silver For 10% off Gerald Celente's prescient Trends Journal, go to https://trendsjournal.com/ and enter the code KNIGHT Find out more about the show and where you can watch it at TheDavidKnightShow.comIf you would like to support the show and our family please consider subscribing monthly here: SubscribeStar https://www.subscribestar.com/the-david-knight-showOr you can send a donation throughMail: David Knight POB 994 Kodak, TN 37764Zelle: @DavidKnightShow@protonmail.comCash App at: $davidknightshowBTC to: bc1qkuec29hkuye4xse9unh7nptvu3y9qmv24vanh7Become a supporter of this podcast: https://www.spreaker.com/podcast/the-david-knight-show--2653468/support.
IVF Clinic Bombing and Pro-Mortalism Ideology (00:02:09 - 00:09:27)Guy Edward Bartkus bombed a Palm Springs IVF clinic, killing himself and injuring five, motivated by pro-mortalism (life causes suffering, death is liberation). His manifesto, hosted on promortalism.com, rails against pro-lifers and life itself, reflecting a nihilistic, anti-human philosophy rooted in online subcultures.Cultural Nihilism and Social Media's Role (00:13:03 - 00:24:28)The bomber's pro-mortalism reflects a broader cultural nihilism, influenced by ideas like Gaia theory (humans as a virus) and amplified by social media platforms. Reddit, TikTok, and Tumblr are criticized as hubs for pseudo-intellectualism, fostering anti-life ideologies among isolated individuals.Bible Engagement as a Positive Trend (00:24:28 - 00:31:02)A LifeWay survey shows 48% of Americans view the Bible as true (up from 36% in 2016), with rising Bible sales and reading. This suggests a growing rejection of secular humanism and a return to spiritual values amid cultural nihilism.Covid as a Scam (Music Man Analogy) (00:41:36 - 00:50:18)A Brownstone Institute article compares the Covid response to The Music Man, where fear (inflated death counts, PCR test misuse) enriched “snake oil salesmen” like Fauci. This mirrors historical fearmongering (9/11, Waco) to erode rights, with elites profiting from compliance.Trump's Tariffs Impact on Small Businesses (01:11:21 - 01:16:20)An NFIB survey shows Trump's unpredictable tariffs are reducing small business optimism (down to 95.8, below the 51-year average), creating market uncertainty akin to Covid-era disruption. Small businesses face tight margins, reduced hiring, and stalled investments, with tech sector impacts highlighted by YouTubers Louis Rossman and Gamers Nexus.DEA Corruption in Drug War (01:27:30 - 01:35:58)An AP article reveals Diego Marin, a Cali cartel figure, evaded capture with DEA complicity, bribing agents while building a $100M money-laundering empire. Compared to Whitey Bulger and Iran-Contra, it's framed as a problem-reaction-solution tactic to expand the police state.Mexican Navy Ship Crash (01:37:07 - 01:39:26)An NBC News report describes a Mexican Navy sailing ship crashing into the Brooklyn Bridge, killing two and injuring 22 due to a mechanical failure. The surreal event stunned New Yorkers, highlighting the unexpected nature of Mexico's sailing navy.CDC Covid Vaccine Recommendations (01:52:26 - 01:56:33)A Wall Street Journal article reports the Trump administration plans to drop routine Covid vaccine recommendations for pregnant women, teenagers, and children, led by HHS Secretary RFK Jr. The host criticizes the CDC's blanket recommendation (everyone 6 months and older) due to no long-term safety data, profit-driven motives, and harmful side effects, arguing the vaccine should be removed entirely.HHS Covid Vaccine Recommendations and Authority (02:05:33 - 02:13:16)Dr. Ruby critiques HHS's plan to stop recommending Covid vaccines for children and pregnant women as a red herring, given its authority over FDA, NIH, CMS, and CDC to demand immediate removal. She warns of deceptive terms like “considering” and questions state chemtrail bans, citing federal exemptions (Title 50, Prep Act) and global air circulation, suspecting controlled opposition.Novavax Approval Critique and Bird Flu (02:21:20 - 02:30:03)The FDA fully approved Novavax's Covid shot, marketed as non-mRNA but using synthetic spike proteins from moth cells, posing risks like myocarditis with no long-term studies. Dr. Ruby warns of off-label use and compares it to Pfizer/Moderna's rollout. She critiques bird flu as a fabricated threat, with chicken culling inflating egg prices and testing economic control, not addressing real disease.Vaccine Shedding and Industry Protections (02:16:43 - 02:51:36)Pfizer's investigator brochure admits Covid vaccine shedding via inhalation and skin contact, raising concerns about unknown contents affecting unvaccinated individuals. Dr. Ruby highlights the vaccine industry's Prep Act immunity, with government payouts in vaccine court, and Pfizer's 50% non-disclosure agreement, allowing undisclosed ingredients, akin to coercive contracts demanding country assets.Follow the show on Kick and watch live every weekday 9:00am EST – 12:00pm EST https://kick.com/davidknightshow Money should have intrinsic value AND transactional privacy: Go to https://davidknight.gold/ for great deals on physical gold/silver For 10% off Gerald Celente's prescient Trends Journal, go to https://trendsjournal.com/ and enter the code KNIGHT Find out more about the show and where you can watch it at TheDavidKnightShow.comIf you would like to support the show and our family please consider subscribing monthly here: SubscribeStar https://www.subscribestar.com/the-david-knight-showOr you can send a donation throughMail: David Knight POB 994 Kodak, TN 37764Zelle: @DavidKnightShow@protonmail.comCash App at: $davidknightshowBTC to: bc1qkuec29hkuye4xse9unh7nptvu3y9qmv24vanh7Become a supporter of this podcast: https://www.spreaker.com/podcast/the-real-david-knight-show--5282736/support.
For years, scientists thought nothing could live above 73℃/163℉. At that temperature, everything boiled to death. But scientists Tom Brock and Hudson Freeze weren't convinced. What began as their simple quest to trawl for life in some of the hottest natural springs on Earth would, decades later, change the trajectory of biological science forever, saving millions of lives—possibly even yours.This seismic, totally unpredictable discovery, was funded by the U.S. government. This week, as the Trump administration slashes scientific research budgets en masse, we tell one story, a parable about the unforeseeable miracles that basic research can yield. After that, a familiar voice raises some essential questions: what are we risking with these cuts? And can we recover?Special thanks to Joanne Padrón Carney, Erin Heath, Valeria Sabate, Gwendolyn Bogard, Meredith Asbury and Megan Cantwell at AAAS. Thank you as well to Gregor Čavlović and Derek Muller and the rest of the Veritasium team.EPISODE CREDITS: Reported by - Latif Nasserwith help from - Maria Paz GutiérrezProduced by - Sarah Qari and Maria Paz GutiérrezOriginal music and sound design and mixing from - Jeremy BloomFact-checking by - Emily Kreigerand Edited by - Alex Neason with help from Sarah QariEPISODE CITATIONS:Videos - Latif also helped make a version of this story with the YouTube channel Veritasium. Articles - Hudson Freeze NYT OPED: Undercutting the Progress of American ScienceBooks -Thomas Brock, A Scientist in Yellowstone National ParkPaul Rabinow's Making PCR: A Story of BiotechnologyPodcasts Episodes:If you haven't heard, listen to our first episode about the Golden Goose awards. Signup for our newsletter!! It includes short essays, recommendations, and details about other ways to interact with the show. Sign up (https://radiolab.org/newsletter)!Radiolab is supported by listeners like you. Support Radiolab by becoming a member of The Lab (https://members.radiolab.org/) today.Follow our show on Instagram, Twitter and Facebook @radiolab, and share your thoughts with us by emailing radiolab@wnyc.org.Leadership support for Radiolab's science programming is provided by the Gordon and Betty Moore Foundation, Science Sandbox, a Simons Foundation Initiative, and the John Templeton Foundation. Foundational support for Radiolab was provided by the Alfred P. Sloan Foundation.
© 2020-2025 Ivy Podcast Discovery LLC
